Popular Searches

Resources

Get in Touch

Kelly Moore
903.877.7732 (o)
903.877.7652 (f)

Publications

Contributions to Clinical and Laboratory Standards Institute (CLSI)

  1. Brown-Elliott BA, Parrish NM, Wengenack NL, on behalf of the CLSI Mycobacterial AST Working Group: Mycobacterium chelonae extended incubation needed for clarithromycin antimicrobial susceptibility testing (AST).  Clinical and Laboratory Standards Institute Update, March 2025.

  2. Parrish, N.M., Wengenack, N.L., Barker, A., Brown-Elliott, B.A., Cirillo, D.M., Harrington, S., Khare, R., Killian, S.B., Pfeltz, R., Richter, E., Rowlinson, M.-C., Zelazny, A.M.  Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes.  Clinical and Laboratory Standards Institute, 2nd ed., CLSI supplement M24S, 2023.

  3. Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM, Conville PS, Desmond EP, Killian SB, Parrish NM, Pfeltz R, Richter E, Turnidge JD:  Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes; 1st ed. Clinical and Laboratory Standards Institute (CLSI), M62, 2018.

  4. Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM, Conville PS, Desmond EP, Killian SB, Parrish NM, Pfeltz R, Richter E, Turnidge JD:  Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes; Standard 3rd ed.  Clinical and Laboratory Standards Institute (CLSI), M24, 2018.

  5. Forbes BA, Miller MB, Banaei N, Brown-Elliott BA, Das S, Pentella MA, Salfinger M, Sharma MK, Somoskovi A, Tans-Hersten J, Tenover FC, Warshauer D, Zelazny, AM:  Laboratory detection and identification of mycobacteria. 2nd ed.  Clinical and Laboratory Standards Institute (CLSI), M48, 2018.

  6. Woods GL, Brown-Elliott BA, Conville PS, Desmond EP, Hall GS, Lin G, Pfyffer GE, Ridderhof JC, Siddiqi SH, Wallace RJ Jr, Warren NG, Witebsky FG:  Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved Standard – Second Edition.  CLSI, M24-A2, 2011.

  7. Forbes BA, Banaei N, Beavis K, Brown-Elliott BA, Della Latta P, Elliott LB,Hall GS, Hanna B, Perkins MD, Siddiqi SH, Wallace RJ Jr, Warren NG:  Laboratory detection and identification of mycobacteria; Approved guideline.  Clinical and Laboratory Standards Institute, M48-A, 2008.

  8. Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyffer GE,  Ridderhof JC, Wallace RJ Jr, Warren NG, Witebsky FG:  Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard.  NCCLS, 23:M24-A, 2003.

  9. Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyffer GE, Plaunt MR, Ridderhof JC, Wallace RJ Jr, Warren NG, Witebsky FG.  Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; tentative standard - Second edition.  NCCLS,20:M24-T2, 2001.

Peer-Reviewed 

  1. Brown-Eliott BA, Wallace Jr. RJ, Graham CI, Kumaraswamy M, Botkin K, Bush G, Esiesimua B, Gonzalez-Ramirez B, Hughes MD, Manchikalapudi AL, Rodriguez E, Somayaji K, Turenne CY, Stobart M, Rabb M, Soualhine H, Wengenack NL, Klapperich C, Viers M, Alexander DC. Phylogenetic diversity and plasmid-mediated macrolide resistance among clinical isolates of Mycobacterium iranicum, an emerging rapidly growing mycobacterial pathogen and proposal of a new species, “Mycobacterium tortolii” sp. nov.  J. Clin. Microbiol. 2026; (in press).

  2. Graham CI, Brown-Elliott BA, Gonzalez-Ramirez B, Somayaji K, Melton S, Wuzinski M, Wengenack NL, Wallace Jr. RJ, Alexander DC. Widespread macrolide resistance among rapidly growing mycobacteria due to plasmids containing erm(55). Sci Rep 16(1):2358, January 2026.

  3. Alexander, D. C., Farquhar, T., Adams, J. M. E., Suchan, D. M., Workman, S. D., Wallace, R. J., Brown-Elliott, B. A., El-Halfawy, O. M., & Cameron, A. D. S. (2025). Macrolide resistance due to erm(55). Microbiol. Spectr. 13(3):e0239724, March 2025.

  4. Brown-Elliott BA, Bush G, Hughes MD, Rodriguez E, Weikel CA, Min SB, Wallace Jr. RJ:  In vitro activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM).  Antimicrob. Agents Chemother.  68(6):e0168423, June 2024.

  5. Wengenack NL, Brown-Elliott BA, Parrish NM, Salfinger M, Turenne CY, Wallace Jr. RJ, Zelazny AM: This is giving me a complex: a practical attempt to streamline nontuberculous mycobacteria nomenclature for clinical purposes. J Clin Microbiol. 62(3):e0153123. February 2024.

  6. Siegel SAR, Griffith DE, Philley JV, Brown-Elliott BA, Brunton AE, Sullivan PE, Fuss C, Strnad L, Wallace Jr. RJ, Winthrop KL: Open-label trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease. Chest. 164(4):846-859. October 2023.

  7. Brown-Elliott BA, Wallace Jr., RJ, Wengenack NL, Workman SD, Cameron ADS, Bush G, Hughes MD, Melton S, Gonzalez-Ramirez B, Rodriguez E, Somayaji K, Klapperich C, Viers M, Bolaji A, Rempel E, and Alexander DC:  Emergence of inducible macrolide resistance in Mycobacterium chelonae due to a broad-host-range plasmid and chromosomal variants of the novel 23S rRNA methylase gene, erm(55). J. Clin. Microbiol. 61(7):e0042823. July 2023; ERRATUM 62(4):e00415-24, April 2024.
    *Selected as Top 4 Best Articles in Journal of Clinical Microbiology 2023

  8. Shallom SJ, Tettelin H, Chandrasekaran P, Park IK, Agrawal S, Arora K, Sadzewicz L, Milestone AM, Aitken ML, Brown-Elliott BA, Wallace Jr., RJ, Sampaio EP, Niederweis M, Olivier KN, Holland SM, and Zelazny AM:  Evolution of Mycobacterium abscessus in the human lung: Cumulative mutations and genomic rearrangement of porin genes in patient isolates. Virulence. 14(1): 2215602. June 2023.

  9. Peters J, Maselli DJ, Mangat M, Coalson JJ, Hinojosa C, Giavedoni L, Brown-Elliott BA, Chan E, and Griffith D:  A marmoset model for Mycobacterium avium complex pulmonary disease. PLoS One. 18(3):e0260563. March 2023.

  10. Jung BG, Dean K, Wadle C, Samten B, Tripathi D, Wallace Jr., RJ, Brown-Elliott BA, Tucker T, Idell S, Philley JV, and Vankayalapati R:  Decreased Interleukin-1 family cytokine production in patients with nontuberculous mycobacterial lung disease. Microbiol Spectr: 10(6):e0311022. December 2022.

  11. Brown-Elliott BA, and Wallace Jr., RJ:  In vitro susceptibility testing of eravacycline     against nontuberculous mycobacteria (NTM).  Antimicrob. Agents Chemother. 66(9):e0068922. August 2022; ERRATUM 66(11):e00689-22. November 2022. 
    *Editor’s Pick for Best Article August 2022 Issue

  12. Jung BG, Samtem B, Dean K, Wallace Jr., RJ, Brown-Elliott BA, Tucker T, Idell S, Philley JV, and Vankayalapati, R:  Early IL-17A production helps establish Mycobacterium intracellulare infection in mice.  PLoS Pathogens. 18(4):e1010454. April 2022.

  13. Davidson RM, Nick SE, Kammlade SM, Vasireddy S, Weakly N, Hasan NA, Epperson LE, Strong M, Nick JA, Brown-Elliott BA, Stout JE, Lewis SS, Wallace Jr., RJ, and Baker AW:  Genomic analysis of a hospital-associated outbreak of Mycobacterium abscessus:  Implications on transmission.  J. Clin. Microbiol. 60(1):e01547-21. January 2022.

  14. Griffith DE, Thomson R, Flume PA, Aksamit TR, Field SK, Addrizzo-Harris DJ, Morimoto K, Hoefsloot W, Mange KC, Yuen DW, Ciesielska M, Wallace Jr., RJ, van Ingen J, Brown-Elliott BA, Coulter C, and Winthrop KL, for the CONVERT Study Group:  Amikacin liposome inhalation suspension for refractory MAC lung disease: Sustainability and durability of culture conversion and safety of long-term exposure.  Chest.  160(3):831-842. September 2021.

  15. Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, Morimoto K, Ruoss SJ, Codecasa LR, Yim JJ, Marras TK, van Ingen J, Wallace RJ Jr, Brown-Elliott BA, Coulter C, Griffith DE. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: A 12-month open-label extension clinical trial. Ann Am Thorac Soc. 18(7):1147-1157. July 2021.

  16. Brown-Elliott BA, and Wallace Jr., RJ:  Comparison of in vitro susceptibility of delafloxacin with ciprofloxacin, moxifloxacin, and other comparator antimicrobials against isolates of nontuberculous mycobacteria.  Antimicrob. Agents Chemother.  65(7):e-000079-21. July 2021.

  17. Davidson RM, Benoit JB, Kammlade SM, Hasan NA, Epperson LE, Smith T, Vasireddy S, Brown-Elliott BA, Nick JA, Olivier KN, Zelazny AM, Daley CL, Strong M, Wallace RJ Jr. Genomic characterization of sporadic isolates of the dominant clone of Mycobacterium abscessus subspecies massiliense. Sci. Rep. 11(1):15336. July 2021.

  18. Brown-Elliott BA, and Wallace Jr., RJ:  In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria (NTM).  Antimicrob. Agents Chemother. 65(3):e-01947-20, March 2021.

  19. Hasse B, Hannan M, Keller PM, Maurer FP, Sommerstein R, Mertz D, Wagner D,  Fernández-Hidalgo N, Nomura J, Manfrin V, Bettex D, Conte AH, Durante-Mangoni E,  Hing-Cheung Tang T, Stuart RL, Lundgren J, Gordon S, Jarashow MC, Schreiber PW,  Niemann S, Kohl TA, Daley C, Stewardson AJ, Whitener CJ, Perkins K, Plachouras D,  Lamagni T, Chand M, Freiberger T, Zweifel S, Sander P, Schulthess B, Scriven J, Sax H,  van Ingen J, Mestres CA, Diekema D, Brown-Elliott BA, Wallace Jr. RJ, Baddour LM,  Miro JM, Hoen B, the M. chimaera ISCVID investigators, Infectious Diseases specialists, Hospital epidemiologists, Microbiologists and molecular typing specialists, Cardiac surgeons/ perfusionists/ cardiologists, Ophthalmology, Anesthesiologists, Public Health, International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass. J. Hosp. Inf. 104:214-235, 2020.

  20. Brown-Elliott BA, Molina S, Fly T, Njie O, Stribley P, Stephenson D, Wallace Jr. RJ,  Perry JD.  Evaluation of a novel rapidly growing mycobacteria medium for isolation of Mycobacterium abscessus complex from respiratory specimens from patients with bronchiectasis.  Heliyon 5(10):e02684, 2019.

  21. Brown-Elliott BA, Woods GL.  Antimycobacterial susceptibility testing of nontuberculous mycobacteria.  J. Clin. Microbiol.  57(10):e00834-19, October 2019.

  22. Brown-Elliott, BA., Fritsche TR, Olson BJ, Vasireddy S, Vasireddy R, Iakhiaeva E, Alame D, Wallace Jr., RJ, Branda JA.  Comparison of two commercial matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for identification of nontuberculous mycobacteria.  Am. J. Clin. Pathol.  XX:1-10, 2019.

  23. Tortoli E, Brown-Elliott BA, Chalmers JD, Cirillo DM, Daley CL, Emler S, Floto RA, Garcia MJ, Hoefsloot W, Koh W-J, Lange C, Loebinger M, Maurer FP, Morimoto K, Niemann S, Richter E, Turenne CY, Wallace Jr., RJ, Wengenack N, van Ingen J:  Same meat, different gravy: ignore the new names of mycobacteria. Eur. Respir. J. 54:1900795, 2019.

  24. Fogelson SB, Camus AC, Lorenz WW, Vasireddy R, Vasireddy S, Smith T, Brown-Elliott BA, Wallace Jr. RJ, Hasan NA, Reischl U, Sanchez S:  Variation among human, veterinary and environmental Mycobacterium chelonae-abscessus complex isolates observed using core genome phylogenomic analysis, targeted gene-comparison, and anti-microbial susceptibility patterns.  PLoS ONE. 14(3):e214274. March 2019.

  25. Brown-Elliott BA, Wallace Jr., RJ:  In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex.  Antimicrob. Agents Chemother.  63(2):e01919-18. February 2019.

  26. Vasireddy R, Vasireddy S, Brown-Elliott BA, Greninger AL, Davidson RM, ARd KL, Turenne CY, Wallace Jr., RJ:  Mycobacterium talmoniae, a potential pulmonary pathogen isolated from multiple patients with bronchiectasis in the United States, including the first case of clinical disease in a patient with cystic fibrosis.  J. Clin. Microbiol.  57(2):e00906-18. February 2019.

  27. Seidelman J, Wallace Jr., RJ, Iakhiaeva E, Vasireddy R, Brown-Elliott BA, McKnight C, Chen LF, Smith T, Lewis SS:  Mycobacterium avium pseudo-outbreak associated with an outpatient bronchoscopy clinic:  Lessons for reprocessing.  Infect Control Hosp. Epidemiol.  40(1):106-108. January 2019.

  28. Brown-Elliott BA, Rubio A, Wallace Jr., RJ:  In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria.  Antimicrob. Agents Chemother.  62(11):e01503-18. November 2018.

  29. van Ingen J, Turenne CY, Tortoli E, Wallace Jr. RJ, Brown-Elliott BA.  2018.  A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review.  Int. J. Syst. Evol. Microbiol.  68(11):3666-3677. September 2018.

  30. Brown-Elliott BA, Simner PJ, Trovato A, Hyle EP, Droz S, Buckwalter SP, Borroni E, Branda JA, Iana E, Mariottini A, Nelson J, Matteelli A, Toney NC, Scarparo C, de Man TJB, Vasireddy R, Gandhi RT, Wengenack NL, Cirillo DM, Wallace Jr., RJ, Tortoli E:  Mycobacterium decipiens sp. nov., a new species closely related to Mycobacterium tuberculosis complex.  Int. J. Sys. Evol. Microbiol. 68:3557-3562. September 2018.

  31. Miller E, Cantrell C, Beard M, Derylak A, Babady NE, McMillen T, Miranda E, Body B, Tang Y-W, Vasireddy R, Vasireddy S, Smith T, Iakhiaeva E, Wallace Jr., RJ, Brown-Elliott BA, Moreno E, Totty H, Deol P:  Performance of Vitek MS v3.0 for identification of Mycobacterium species from patient samples by use of automated liquid medium systems.  J. Clin. Microbiol. 56(8):e00219-18. August 2018.

  32. Philley JV, Hertweck KL, Kannan A, Brown-Elliott BA, Wallace Jr. RJ, Kurdowska A, Ndetan H, Singh KP, Miller EJ, Griffith DE, Dasgupta S.  2018.  Sputum detection of predisposing genetic mutations in women with pulmonary nontuberculous mycobacterial disease.  Nature – Scientific Reports. 8:11336. July 2018.

  33. Body BA, Beard MA, Slechta ES, Hanson KE, Barker AP, Babady NE, McMillen T, Tang, Y-W, Brown-Elliott BA, Iakhiaeva E, Vasireddy R, Vasireddy S, Smith T, Wallace Jr., RJ, Turner S, Curtis L, Butler-Wu S, Rychert J:  Evaluation of the Vitek MS v3.0 matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of Mycobacterium and Nocardia species.  J. Clin. Microbiol.  56(6):e00237-18. June 2018.

  34. Welsh, O, Salinas-Carmona MC, Brown-Elliott BA, Smith T, Cardenas-De La Garza JA, Wallace Jr., RJ:  Disseminated actinomycetoma due to Nocardia wallacei.  Int. J. Dermatol.  2018; 57(5):580-582. May 2018.

  35. Conville P, Brown-Elliott BA, Smith T, Zelazny AM:  The complexities of Nocardia taxonomy and identification.  J. Clin. Microbiol. 56(1): pii:e01419-17, 2017.

  36. Brown-Elliott BA, Wallace Jr., RJ:  In vitro susceptibility testing of tedizolid against isolates of Nocardia.  Antimicrob. Agents Chemother.  61(12):e01537-17, 2017.

  37. Paniz-Mondolfi A, Greninger AL, Ladutko L, Brown-Elliott BA, Vasireddy R, Jakubiec W, Vasireddy S, Wallace Jr. RJ, Simmon KE, Dunn BE, Jackoway G, Vora SB, Quinn KK, Qin X, Campbell S:  Mycobacterium grossiae sp. nov., a rapidly growing, scotochromogenic species isolated from human clinical respiratory and blood culture specimens.  Int. J. Syst. Evol. Microbiol.  67(11):4345-4351, 2017.

  38. Brown-Elliott BA, Wallace Jr., RJ:  In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria.  J. Clin. Microbiol. 55(6):1747-1754, 2017.

  39. Baker AW, Lewis SS, Alexander BD, Chen LF, Wallace Jr. RJ, Brown-Elliott BA,  Isaacs PJ, Pickett LC, Patel CB, Smith PK, Reynolds JM, Engel J, Wolfe CR,  Milano CA, Schroder JN, Davis RD, Hartwig MG, Stout JE, Strittholt N, Maziarz EK, Saullo JH, Hazen KC, Walczak Jr. RJ, Vasireddy R, Vasireddy S,  McKnight CM, Anderson DJ, Sexton DJ:  Two-phase hospital-associated outbreak of Mycobacterium abscessus: Investigation and mitigation. Clin. Infect. Dis.  64:902-911, 2017.

  40. Olivier KN, Griffith DE, Eagle G, McGinnis li JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R., Wallace Jr., RJ:  Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease.  Am. J. Crit. Care Med. 195(6):814-823, 2017.

  41. Philley JV, Kannan A, Griffith DE, Devine MS, Benwill JL, Wallace Jr., RJ, Brown-Elliott BA, Thakkar F, Taskar V, Fox JG, Alqaid A, Bains H, Gupta S, Dasgupta S:  Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.  Oncotarget. 8(11):18070-18081, 2017.

  42. Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron ADS, Wallace Jr., RJ:  Emergence of mmpT5 during bedaquiline treatment of Mycobacterium intracellulare lung disease.  J. Clin. Microbiol. 55(2):574-584, 2017.

  43. Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace Jr., RJ:  In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex.  Antimicrob. Agents Chemother. 61(2):01798-16, 2017.

  44. Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Cardoso Leão S, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, Philley JV, Baldan R, Campana S, Cariani L, Colombo C, Taccetti G, Teri A, Niemann S, Wallace Jr. RJ, Cirillo DM:  Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus, Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense subsp. nov.  Int. J. Sys. Evol. Microbiol. 66:4471-4479, 2016.

  45. Wu T-S, Yang C-H, Brown-Elliott BA, Chao A-S, Leu H-S, Wu T-L, Lin C-S, Griffith DE, Chiu C-H:  Postcesarean section wound infection caused by Mycobacterium massiliense.  J. Microbiol. Immunol. Infect.  49:955-961, 2016.

  46. Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace Jr. RJ:  In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and Nocardia.  J. Clin. Microbiol.  54(6):1586-1592, 2016.

  47. Vasireddy, R., S. Vasireddy, Brown-Elliott BA, Wengenack NL, Eke UA, Benwill JL, Turenne C, Wallace Jr. RJ:  Mycobacterium arupense, Mycobacterium heraklionense, and a newly proposed species, “Mycobacterium virginiense” sp. nov., but not Mycobacterium nonchromogenicum, as species of the Mycobacterium terrae complex causing tenosynovitis and osteomyelitis.  J. Clin. Microbiol.  54(5):1340-1351, 2016; ERRATUM 55(3):985, 2017.

  48. Iakhiaeva E, Howard S, Brown-Elliott BA, McNulty S, Falkinham, III JO,  Newman K, Williams M, Kwait R, Lande L, Vasireddy R, Turenne C,  Wallace Jr. RJ:  Variable-number tandem-repeat (VNTR) analysis of respiratory and household water biofilm isolates of “Mycobacterium avium subsp. hominissuis” with establishment of a PCR database.  J. Clin. Microbiol. 54(4):891-901, 2016.

  49. Griffith DE, Adjemian J, Brown-Elliott BA, Prevots DR, Philley JV, Olivier KN, Wallace Jr. RJ:  Cure not possible, by definition.  Reply:  Am. J. Respir. Crit. Care Med.  192:1256-1257, 2015.

  50. Canterino J, Paniz-Mondolfi A, Brown-Elliott BA, Vientos W, Vasireddy R, Wallace RJ Jr., Campbell S:  Nocardia thailandica pulmonary nocardiosis in a solid organ post-transplant patient.  J. Clin. Microbiol. 53:3689-3690, 2015.

  51. Griffith DE, Adjemian J, Brown-Elliott BA, Philley JV, Prevots DR, Gaston C, Olivier KN, Wallace RJ:  Semi-quantitative culture analysis during therapy for Mycobacterium avium complex (MAC) lung disease.  Am. J. Resp. Crit Care Med. 192:754-760, 2015.

  52. Philley JV, Wallace RJ Jr., Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE:  Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease.  Chest.  148:499-506, 2015.

  53. Lourenço Nogueira C, Simmon KE, Chimara E, Cnockaert M, Carlos Palomino J, Martin A, Vandamme P, Brown-Elliott BA, Wallace Jr. RJ, Cardoso Leão S:  Mycobacterium franklinii sp. nov., a species closely related to members of the Mycobacterium chelonae-Mycobacterium abscessus group.  Int. J. Syst. Evol. Microbiol. 65:2148-2153, 2015.

  54. Griffith DE, Brown-Elliott BA, Wallace Jr. RJ:  Hit the road, MAC, and don’t you come back no more.  Am. J. Resp. Crit. Care Med. 191:1222-1224, 2015.

  55. Griffith DE, Philley JV, Brown-Elliott BA, Benwill J, Shepherd S, York D, Wallace RJ Jr:  The significance of M. abscessus ssp. abscessus isolation during Mycobacterium avium complex (MAC) lung disease therapy.  Chest. 147:1369-1375, 2015.

  56. Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST, Nash K, Parodi N, Strong A, Gee M, Smith T, and Wallace RJ Jr.: Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs.  J. Clin. Microbiol.  53:1211-1215, 2015; ERRATUM 54:1172, 2016.

  57. Griffith DE, Brown-Elliott BA, Benwill JL, Wallace RJ Jr.:  Mycobacterium abscessus “Pleased to meet you, hope you guess my name...”  Ann. Am. Thorac. Soc. 12:436-439, 2015.

  58. Brown-Elliott BA, Hanson K, Vasireddy S, Iakhiaeva E, Nash K, Vasireddy R, Parodi N, Smith T, Gee M, Strong A, Barker A, Cohen S, Muir H, Slechta E, Wallace RJ Jr.:  Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group based on in vitro clarithromycin susceptibility. J. Clin Microbiol. 53:875-878, 2015.

  59. Brown-Elliott BA, Conville P, Wallace RJ Jr.: Current status of Nocardia taxonomy and recommended identification methods.  Clin. Microbiol. Newsletter.  37:25-32, 2015.

  60. Simner PJ, Hyle EP, Buckwalter SP, Branda JA, Brown-Elliott BA, Franklin Jm, Toney NC, de Man TJB, Wallace RJ Jr., Vasireddy R, Gandhi RT, Wengenack NL: Tenosynovitis caused by a novel nontuberculous Mycobacterium species initially misidentified as a member of the Mycobacterium tuberculosis complex.  J. Clin. Microbiol.  52:4414-4418, 2014.

  61. Beam E, Vasoo S, Simner P, Rizzo M, Mason E, Walker R, Deml S, Brown-Elliott BA, Wallace RJ, Wengenack N, Sia I:  Mycobacterium arupense flexor tenosynovitis: A case report and a review of antimicrobial susceptibility profiles for 40 clinical isolates. J. Clin. Microbiol.  2014; 52:2706-2708, 2014.

  62. Paniz-Mondolfi A, Ladutko L, Brown-Elliott BA, Vasireddy R, Vasireddy S, Wallace Jr., RJ, Jakubiec W, Brecher S, Campbell S:  First report of Mycobacterium canariasense catheter-related bacteremia in the Americas.  J. Clin. Microbiol. 52: 2265-2269, 2014.

  63. Wallace RJ Jr., Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE:  Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease.  Chest.  146(2):276-282, 2014.

  64. Wallace RJ Jr., Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B: Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections.  J. Antimicrob. Chemother.  69:1945-1953, 2014.

  65. Tettelin H, Davidson RM, Agrawal S, Aitken ML, Shallom S, Hasan NA, Strong M, de Moura VCN, De Groote MA, Duarte RS, Hine E, Parankush S, Su Q, Daugherty SC, Fraser CM, Brown-Elliott BA, Wallace RJ, Holland SM, Sampaio EP, Olivier KN, Jackson M, Zelazny AM:  High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks.  Emerg. Infect. Dis. 20:364-371, 2014.

  66. Howard ST, Newman KL, McNulty S, Brown-Elliott BA, Vasireddy R, Bridge L, Wallace RJ Jr.: Insertion site and distribution of a genomic island conferring DNA phosphorothioation in the Mycobacterium abscessus complex.  Microbiology.  159:2323-2332, 2013.

  67. Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods G, Stout JE, Wolfe CR, Turenne C, Wallace RJ Jr.: In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.  J. Clin. Microbiol.  51:3389-3394, 2013; ERRATUM 52:1311, 2014.

  68. Wallace RJ Jr, Iakhiaeva E, Williams MD, Brown-Elliott BA, Vasireddy S, Vasireddy R, Lande L, Peterson DD, Sawicki J, Kwait R, Tichenor WS, Turenne C, Falkinham III JO: Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease.  J. Clin. Microbiol.  51:1747-1752, 2013.

  69. Iakhiaeva E, McNulty S, Brown-Elliott BA, Falkinham JO III, Williams MD, Vasireddy R, Wilson RW, Turenne C, Wallace RJ Jr.: Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat (MIRU-VNTR) genotyping of Mycobacterium intracellulare for strain comparison with establishment of a PCR-based database.  J. Clin. Microbiol.  51: 409-416, 2013.

  70. McGhie T, Fader R, Carpenter J, Brown-Elliott BA, Vasireddy R, Wallace RJ Jr.:  Nocardia neocaledoniensis as a cause of skin and soft tissue infection.  J. Clin. Microbiol.  50:3139-3140, 2012; ERRATUM  51:384, 2013.

  71. Tichenor WS, Thurlow J, McNulty S, Brown-Elliott BA, Wallace RJ Jr., Falkinham III JO: Nontuberculous mycobacteria in household plumbing as a possible cause of chronic rhinosinusitis.  Emerg. Infect. Dis.  18:1612-1617, 2012.

  72. Brown-Elliott BA, Nash KA, Wallace RJ Jr: Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.  Clin. Microbiol. Rev.  25:545-582, 2012.

  73. Brown-Elliott BA, Mann LB, Hail D, Whitney Cl, Wallace RJ Jr: Antimicrobial susceptibility of nontuberculous mycobacteria from eye infections.  Cornea.  31:900-906, 2012.

  74. Brown-Elliott, B. A., and R. J. Wallace Jr.:  Enhancement of conventional phenotypic methods with molecular-based methods for the more definitive identification of nontuberculous mycobacteria.  Clin.  Microbiol. Newsletter 34:109-115, 2012.

  75. Conville PS, Brown-Elliott BA, Wallace RJ Jr., Witebsky FG, Koziol D, Hall GS, Killian SB, Knapp CC, Warshauer D, Van T, Wengenack NL, Deml S, Woods GL:  Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species.  J. Clin. Microbiol.  50:1270-1280, 2012.

  76. Brown-Elliott BA, Biehle J, Conville PS, Cohen S, Saubolle M, Sussland D, Wengenack N, Kriel K, Bridge L, McNulty S, Vasireddy R, Wallace RJ Jr: Sulfonamide resistance in isolates of Nocardia spp. from a U.S. multicenter survey.  J. Clin. Microbiol.  50:670-672, 2012.

  77. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, McNulty S, Wallace RJ Jr.:  Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center.  Am. J. Respir. Crit. Care Med.  185:231-232, 2012.

  78. Brown-Elliott BA, Wallace RJ, Tichindelean C, Sarria JC, McNulty S, Vasireddy R, Bridge L, Mayhall CG, Turenne C, Loeffelholz M: Five-year outbreak of community- and hospital-acquired Mycobacterium porcinum infections related to public water supplies.  J. Clin. Microbiol.  49:4231-4238, 2011.

  79. Simmon KE, Brown-Elliott BA, Ridge PG, Durtschi JD, Bridge Mann L, Slechta  ES, Stiegerwalt AG, Moser BD, Whiteney AM, Brown JM, Koelkerding KV, McGowan KL, Reilly AF, Kirn TJ, Butler WR, Edlestein PH, Wallace RJ Jr., Petti CA.  Mycobacterium chelonae-abscessus complex associated with sinopulmonary disease, Northeastern USA0. Emerg. Infect. Dis.  17:1692-1700, 2011.

  80. Brown-Elliott BA, Wallace RJ Jr., Petti CA, Mann LB, McGlasson M, Chihara S, Smith GL, Painter P, Hail D, Wilson R, Simmon KE: Mycobacterium neoaurum and Mycobacterium bacteremicum sp. nov. as causes of mycobacteremia.  J. Clin. Microbiol.  48:4377-4385, 2010.

  81. Metersky ML, Bean SC, Meyer JD, Mutambudzi M, Brown-Elliott BA, Wechsler ME, Wallace RJ Jr: Trombone player’s lung.  Chest.  138:754-755, 2010.

  82. Babady NE, Hall L, Abbenyi AT, Eisberner JJ, Brown-Elliott BA, Pratt CJ, McGlasson MC, Beirle DK, Wohlfiel SL, Deml SM, Wallace RJ Jr, Wengenack NL:  Evaluation of Mycobacterium avium  complex clarithromycin susceptibility testing using SLOMYCO sensititre panels and JustOne strips.  J. Clin. Microbiol.  48:1749-1752, 2010.

  83. Simmon KE, Low YY, Brown-Elliott BA, Wallace RJ Jr., Petti CA: Phylogenetic analysis of Mycobacterium aurum and Mycobacterium neoaurum with redescription of M. aurum culture collection strains.  Int. J. Syst. Evol. Microbiol.  59:1371-1375, 2009.

  84. Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F, Conlan S, McNulty S, Brown-Elliott BA, Wallace RJ Jr., Oliver KN, Holland SM, Sampaio EP:  Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii.  J. Clin. Microbiol.  47:1985-1995, 2009.

  85. Nash KA, Brown-Elliott BA, Wallace RJ Jr.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.  Antimicrob. Agents Chemother.  53:1367-1376, 2009.

  86. Wünschmann A, Armien A, Harris NB, Brown-Elliott BA, Wallace RJ Jr., Rasmussen J, Willette M, Wolf T:  Disseminated panniculitis in a bottlenose dolphin (Tursiops truncatus) due to Mycobacterium chelonae infection.  J. Zoo Wild. Med.  39:412-420, 2008.

  87. Conville PS, Brown JM, Steigerwalt AG, Brown-Elliott BA, Witebsky FG: Nocardia wallacei sp. nov. and Nocardia blacklockiae sp. nov., human pathogens and members of the “Nocardia transvalensis” complex.  J. Clin. Microbiol.  46:1178-1184, 2008.

  88. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr., Winthrop K, on behalf of the American Thoracic Society Mycobacterial Disease Subcommittee:  An official ATS/IDSA statement:  Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.  Am. J. Respir. Crit. Care Med.  175:367-416, 2007.

  89. Butler WR, Sheils CA, Brown-Elliott BA, Charles N, Colin AA, Gant MJ, Goodill J, Hindman D, Toney SR, Wallace RJ Jr., Yakrus MA:  First isolations of Segniliparus rugosus from patients with cystic fibrosis.  J. Clin. Microbiol.  45:3449-3452, 2007.

  90. Tortoli E, Galli L, Andebirhan T, Baruzzo S, Chiappini E, de Martino M, Brown-Elliott BA:  The first case of Mycobacterium sherrisii disseminated in a child with AIDS.  AIDS.  21:1496-1498, 2007.

  91. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr:  Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy.  Clin. Microbiol. Rev.  19:259-282, 2006.

  92. Vera-Cabrera L, Brown-Elliott BA, Wallace RJ Jr., Ocampo-Candiani J, Welsh O, Choi, SH, Molina-Torres CA: In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.  Antimicrob. Agents Chemother.  50:4027-4029, 2006.

  93. Nash KA, Andini N, Zhang Y, Brown-Elliott BA, Wallace RJ Jr.: Intrinsic macrolide resistance in rapidly growing mycobacteria.  Antimicrob. Agents Chemother.  50:3476-3478, 2006.

  94. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K,  Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ Jr:  Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.  Am. J. Respir. Crit. Care Med. 174:928-934, 2006.

  95. Wallace RJ Jr, Brown-Elliott BA, Brown J, Steigerwalt AG, Hall L, Woods G, Cloud J, Mann L, Wilson R, Crist C, Jost KC Jr, Byrer DE, Tang J, Cooper J, Stamenova E, Campbell B, Wolfe J, Turenne C:  Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense.  J. Clin. Microbiol.  43:5925-5935, 2005.

  96. Cloud JL, Hoggan K, Belousov E, Cohen S, Brown-Elliott BA, Mann L, Wilson R, Aldous W, Wallace Jr. RJ, Woods GL:  Use of the MGB eclipse system and SmartCycler PCR for differentiation of Mycobacterium chelonae and M. abscessus.  J. Clin. Microbiol.   43:4205-4207, 2005.

  97. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr:  Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.  J. Antimicrob. Chemother.  55:170-177, 2005.

  98. Conger NA, O’Connell R, Laurel V, Olivier K, Graviss EA, Williams-Bouyer N, Zhang Y,  Brown-Elliott B, Wallace RJ Jr.  Mycobacterium simiae outbreak associated with a hospital water supply.  Infect. Control Hosp. Epidemiol.  25:1050-1055, 2004.

  99. Wallace RJ Jr, Brown-Elliott BA, Wilson RW, Mann L, Hall L, Zhang Y, Jost KC Jr, Brown JM, Kabani A, Schinsky MF, Steigerwalt AG, Crist CJ, Roberts GD, Blacklock Z, Tsukamura M, Silcox V, Turenne C:  Clinical and laboratory features of Mycobacterium porcinum.  J. Clin. Microbiol.  42:5689-5697, 2004.

  100. Patel JB, Wallace RJ Jr., Brown-Elliott BA, Taylor T, Imperatrice C, Leonard DGB, Wilson RW, Mann L, Jost KC, Nachamkin I:  Sequence-based identification of aerobic actinomycetes.  J. Clin. Microbiol.  42:2530-2540, 2004.

  101. Schinsky MF, Morey RE, Steigerwalt AG, Douglas MP, Wilson RW, Floyd MM, Butler WR, Daneshvar MI, Brown-Elliott BA, Wallace RJ Jr, McNeil MM, Brenner DJ, Brown JM:  Taxonomic variation in the Mycobacterium fortuitum third biovariant complex:  description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.  Int. J. Syst. Evol. Microbiol.  54:1653-1667, 2004.

  102. Zhang Y, Mann LB, Wilson RW, Brown-Elliott BA, Vincent V, Iinuma Y, Wallace RJ Jr:  Molecular analysis of Mycobacterium kansasii isolates from the United States.  J. Clin. Microbiol.  42:119-125, 2004.

  103. Griffith DE, Brown-Elliott BA, Wallace RJ Jr:  Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: Results of a preliminary study.  Clin. Infect. Dis.  37:1178-1182, 2003.

  104. Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr:  In vitro activity of linezolid against slowly growing nontuberculous mycobacteria.  Antimicrob. Agents Chemother.  47:1736-1738, 2003.

  105. Tiwari TSP, Ray B, Jost KC Jr., Rathod MK, Zhang Y, Brown-Elliott BA, Hendricks K, Wallace RJ Jr:  Forty years of disinfectant failure:  Outbreak of postinjection Mycobacterium abscessus infection caused by contamination of benzalkonium chloride.  Clin. Infect. Dis.  36:954-962, 2003.

  106. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee J-H, Zhang Y, Brown-Elliott BA, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR, for the Nontuberculous Mycobacteria in Cystic Fibrosis Study Group.  Nontuberculous mycobacteria:  I: Multicenter prevalence study in cystic fibrosis.  Am. J. Respir. Crit. Care Med.  167:828-834, 2003.

  107. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, Schentag JJ, Gimbel JF, Apodaca A, Schwartz MA, Rakita RM, Wallace RJ Jr: Clinical experience with linezolid for the treatment of Nocardia infection.  Clin. Infect. Dis.  36:313-318, 2003.

  108. Woods GL, Williams-Bouyer N, Wallace RJ Jr, Brown-Elliott BA, Witebsky FG, Conville PS, Plaunt M, Hall G, Aralar P, Inderlied C:  Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.  J. Clin. Microbiol.  41:627-631, 2003.

  109. Brown-Elliott BA, Wallace RJ Jr:  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.  Clin. Microbiol. Rev.  15:716-746, 2002.

  110. Brown-Elliott BA, Griffith DE, Wallace RJ Jr:  Diagnosis of nontuberculous mycobacterial infections.  Clin. Lab. Med.  22:911-925, 2002.

  111. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, Mann L, Wilson RW:  Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.  Antimicrob. Agents Chemother.  46:3283-3285, 2002.

  112. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW:  Comparison of  in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.  Antimicrob. Agents. Chemother.  46:3164-3167, 2002.

  113. Wallace RJ Jr, Brown-Elliott BA, Hall L, Roberts G, Wilson RW, Mann LB, Crist CJ, Chiu SH, Dunlap R, Garcia MJ, Bagwell JT, Jost KC Jr:   Clinical and laboratory features of Mycobacterium mageritense.  J. Clin. Microbiol.  40:2930-2935, 2002.

  114. Wallace RJ Jr, Zhang Y, Brown-Elliott BA, Yakrus MA, Wilson RW, Mann L, Couch L, Girard WM, Griffith DE:  Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis.  J. Infect. Dis.  186:266-273, 2002.

  115. Meyers H, Brown-Elliott BA, Moore D, Curry J, Truong C, Zhang Y, Wallace RJ Jr:  An outbreak of Mycobacterium chelonae infection following liposuction.  Clin. Infect. Dis.  34:1500-1507, 2002.

  116. Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, Crist CJ, Mann LB:  Successful treatment of disseminated Mycobacterium chelonae infection with linezolid.  Clin. Infect. Dis.  33:1433-1434, 2001.

  117. Wilson RW, Steingrube VA, Böttger EC, Springer B, Brown-Elliott BA, Vincent V, Jost KC Jr., Zhang Y, Garcia MJ, Chiu SH, Onyi GO, Rossmoore H, Nash DR, Wallace RJ Jr:  Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy.  Int. J. Syst. Evol. Microbiol. 51:1751-1764, 2001.

  118. Bange F-C, Brown BA, Smaczny C, Wallace RJ Jr, Böttger EC: Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic.  Clin. Infect. Dis.  32:1648-1650, 2001.

  119. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr: Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.  Clin. Infect. Dis.  32:1547-1553, 2001.

  120. Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr: In Vitro Activities of linezolid against multiple Nocardia species.  Antimicrob. Agents Chemother.  45:1295-1297, 2001.

  121. Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW: Activities of linezolid against rapidly growing mycobacteria.  Antimicrob. Agents Chemother.  45:764-767, 2001.

  122. Green SL, Lifland BD, Bouley DM, Brown BA, Wallace RJ Jr, Ferrell JE Jr: Disease attributed to Mycobacterium chelonae in South African clawed frogs (Xenopus laevis).  Comparative Med.  50:675-679, 2000.

  123. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr: Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.  Clin. Infect. Dis.  30:288-292, 2000.

  124. Woods, GL, Bergmann JS, Witebsky FG, Fahle GA, Boulet B, Plaunt M, Brown BA, Wallace RJ Jr, Wanger A: Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.  J. Clin. Microbiol.  38:656-661, 2000.

  125. Brown BA, Springer B, Steingrube VA, Wilson RW, Pfyffer GE, Garcia MJ, Menendez MC, Rodriguez-Salgado B, Jost KC Jr., Chiu SH, Onyi GO, Böttger EC, Wallace RJ Jr: Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial Taxonomy.  Intern. J. Syst. Bacteriol.  49:1493-1511, 1999.

  126. Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Wanger A, Boulet B, Plaunt M, Brown BA, Wallace RJ Jr: Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.  J. Clin. Microbiol.  37:1676-1682, 1999.

  127. Brown BA, Lopes JO, Wilson RW, Costa JM, de Vargas AC, Alves SH, Klock C, Onyi GO, Wallace RJ Jr: Disseminated Nocardia pseudobrasiliensis infection in a patient with AIDS in Brazil.  Clin. Infect. Dis. 28:144-145, 1999.

  128. Wallace RJ Jr, Zhang Y, Brown BA, Dawson D, Murphy DT, Wilson R, Griffith DE:  Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis.  Am. J. Respir. Crit. Care Med.  158:1235-1244, 1998.

  129. Nelson KG, Griffith DE, Brown BA, Wallace RJ Jr: Results of operation in Mycobacterium avium-intracellulare lung disease.  Ann. Thorac. Surg.  66:325-330, 1998.

  130. Lai KK, Brown BA, Westerling JA, Fontecchio SA, Zhang Y, Wallace RJ Jr: Long-term laboratory contamination by Mycobacterium abscessus resulting in two pseudo-outbreaks: Recognition with use of random amplified polymorphic DNA (RAPD) polymerase chain reaction.  Clin. Infect. Dis.  27:169-175, 1998.

  131. Burman WJ, Stone BL, Brown BA, Wallace RJ Jr., Böttger EC: AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin.  Diagn. Microbiol. Infect. Dis.  31:369-371, 1998.

  132. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace RJ Jr: A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae.  J. Infect. Dis. 177:1573-1581, 1998.

  133. Jarboe E, Stone BL, Burman WJ, Wallace RJ Jr, Brown BA, Reves RR, Wilson ML:  Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin.  Diagn. Microbiol. Infect. Dis.  30:197-203, 1998.

  134. Wright PW, Wallace RJ Jr, Wright NW, Brown BA, Griffith DE: Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria.  J. Clin. Microbiol.  36:1046-1049, 1998.

  135. Wilson RW, Steingrube VA, Brown BA, Wallace RJ Jr: Clinical application of PCR-restriction enzyme pattern analysis for rapid identification of aerobic actinomycete isolates.  J. Clin. Microbiol.  36:148-152, 1998.

  136. Zhang Y, Rajagopalan M, Brown BA, Wallace RJ Jr: Randomly amplified polymorphic DNA PCR for comparison of Mycobacterium abscessus strains from nosocomial outbreaks.  J. Clin. Microbiol.  35:3132-3139, 1997.

  137. Wilson, RW, Steingrube VA, BA Brown, Blacklock Z, Jost Jr. KC, McNabb A, Colby WD, Biehle JR, Gibson JL, Wallace RJ Jr: Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCR-restriction fragment length polymorphism analysis.  J. Clin. Microbiol.  35:2235-2242, 1997.

  138. Villanueva A, Calderon RV, Vargas BA, Ruiz F, Aguero S, Zhang Y, Brown BA, Wallace RJ Jr:  Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction.  Clin. Infect. Dis.  24:1147-1153, 1997.

  139. Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr:  Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease.  Clin. Infect. Dis.  24:958-964 1997.

  140. Steingrube, VA, Wilson RW, Brown BA, Jost KC Jr., Blacklock Z, Gibson JL, Wallace RJ Jr:  Rapid identification of clinically significant species and taxa of aerobic actinomycetes, including Actinomadura, Gordonia, Nocardia, Rhodococcus, Streptomyces, and Tsukamurella isolates, by DNA amplification and restriction endonuclease analysis.  J. Clin. Microbiol.  35:817-822, 1997.

  141. Brown BA, Wallace RJ Jr., Griffith DE, Warden R: Clarithromycin-associated digoxin toxicity in the elderly.  Clin. Infect. Dis.  24:92-93, 1997.

  142. Griffith DE, Brown BA, Wallace RJ Jr: Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus - negative patients who are receiving multidrug regimens for pulmonary Mycobacterium  avium complex disease.  Clin. Infect. Dis.  23:1321-1322, 1996.

  143. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr:  Azithromycin Activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus.  Clin. Infect. Dis.  23:983-989, 1996.

  144. Meier A, Heifets L, Wallace RJ Jr., Zhang Y, Brown BA, Sander P,  Böttger EC: Molecular mechanisms of clarithromycin resistance in Mycobacterium avium:  observation of multiple 23S rDNA mutations in a clonal population.  J. Infect. Dis.  174:354-360, 1996

  145. Wallace RJ Jr., Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, Böttger EC: Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus.  Antimicrob. Agents Chemother.  40:1676-1681, 1996.

  146. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT: Clarithromycin regimens for pulmonary Mycobacterium avium complex.  Amer. J. Respir. Crit. Care Med. 153:1766-1772, 1996.

  147. Brown, BA, Wallace RJ Jr., Onyi GO: Activities of the glycylcyclines N, N-dimethylglycylamido-minocycline and N, N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.  Antimicrob. Agents Chemother.  40:874-878, 1996.

  148. Steingrube VA, Brown BA, Gibson JL, Wilson RW, Brown J, Blacklock Z, Jost K, Locke S, Ulrich RF, Wallace RJ Jr: DNA amplification and restriction endonuclease analysis for differentiation of 12 species and taxa of Nocardia, including recognition of four new taxa within the Nocardia asteroides complex.  J. Clin. Microbiol.  33:3096-3101, 1995.

  149. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr:  Adverse event associated with high-dose rifabutin in macrolide-including regimens for the treatment of Mycobacterium avium complex lung disease.  Clin. Infect. Dis.  21:594-598, 1995.

  150. Wallace RJ Jr., Brown BA, Blacklock Z, Ulrich R, Jost K, Brown JM, McNeil MM, Onyi G, Steingrube VA, Gibson JL:  New Nocardia taxon among isolates of Nocardia brasiliensis associated with invasive disease.  J. Clin. Microbiol.  33:1528-1533, 1995.

  151. Steingrube VA, Gibson JL, Brown BA, Zhang Y, Wilson RW, Rajagopalan M, Wallace RJ Jr:  PCR amplification and restriction endonuclease analysis of a 65-Kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria.  J. Clin. Microbiol.  33:149-153, 1995.

  152. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K:  Reduced serum levels of clarithromycin in patients with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection.  J. Infect. Dis.  171:747-750, 1995.

  153. Brown BA, Wallace RJ Jr, Griffith DE, Girard W:  Clarithromycin-induced hepatotoxicity.  Clin. Infect. Dis.  20:173-174, 1995.

  154. Pang Y, Brown BA, Steingrube VA, Wallace RJ Jr, Roberts MC:  Tetracycline resistance determinants in Mycobacterium and Streptomyces species.  Antimicrob. Agents Chemother.  38:1408-1412, 1994.

  155. Franklin DJ, Starke JR, Brady MT, Brown BA, Wallace RJ Jr:  Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus:  A new clinical entity?  Amer. J. Otol.  3:313-320, 1994.

  156. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH:  Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.  Amer. Rev. Resp. Dis.  149:1335-1341, 1994.

  157. Wallace RJ Jr., Dunbar D, Brown BA, Onyi G, Dunlap R, Ahn CH, Murphy D:  rifampin-resistant Mycobacterium kansasii.  Clin. Infect. Dis.  18:736-743, 1994.

  158. Meier A, Kirschner P, Burkhardt S, Steingrube VA, Brown BA, Wallace RJ Jr, Böttger E:  Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare.  Antimicrob. Agents Chemother.  38:381-384, 1994.

  159. Wallace RJ Jr, Zhang Y, Brown BA, Fraser V, Mazurek GH, Maloney S:  DNA Large Restriction fragment patterns of sporadic and epidemic nosocomial strains of Mycobacterium chelonae and Mycobacterium abscessus.  J. Clin. Microbiol.  31:2697-2701, 1993.

  160. Wallace RJ Jr, Silcox VA, Tsukamura M, Brown BA, Kilburn JO, Butler WR, Onyi G:  Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.  J. Clin. Microbiol.  31:3231-3239, 1993.

  161. Steingrube VA, Wallace RJ Jr, Brown BA, Zhang Y, Steele LC, Young G, Nash DR:  partial characterization of Nocardia farcinica b-lactamases.  Antimicrob. Agents Chemother.  37:1850-1855, 1993.

  162. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA:  Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae.  Ann. Int. Med. 119:482-486, 1993.

  163. Wallace RJ Jr, Brown BA, Griffith DE.  Drug intolerance to high-dose clarithromycin among elderly patients.  Diagn. Microbiol. Infect. Dis.  16:215-221, 1993.

  164. Mazurek GH, Hartman S, Zhang Y-S, Brown BA, Hector JSR, Murphy D, Wallace RJ Jr.  Large DNA restriction fragment polymorphism in the Mycobacterium avium-M. intracellulare complex: a potential epidemiologic tool.  J. Clin. Microbiol.  31:390-394. 1993.

  165. Wallace, RJ Jr, Brown BA, Onyi G.  Skin, soft tissue, and bone infections due to Mycobacterium chelonae: Importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.  J. Inf. Dis. 166:405-412, 1992.

  166. Zhang Y, Wallace RJ Jr, Steingrube VA, Brown BA, Nash DR, Silcox VA, Tsukamura M:  Isoelectric focusing patterns of b-lactamases in the rapidly growing mycobacteria and potential use as a taxonomic tool.  Tuberc. Lung Dis.  73:337-344, 1992.

  167. Brown BA, Wallace RJ Jr., Onyi G.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.  Antimicrob. Agents Chemother. 36:1987-1990, 1992.
  168. Hector, JRS, Pang Y, Mazurek GH, Zhang Y, Brown BA, Wallace RJ Jr. Large restriction fragment patterns of genomic Mycobacterium fortuitum DNA as strain-specific markers and their use in epidemiologic investigation of four nosocomial outbreaks. J. Clin. Microbiol. 30:1250-1255, 1992.

  169. Burns, DN, Wallace RJ Jr, Schultz M, Zhang Y, Zubairi S, Pang Y, Gibert C, Brown BA, Noel E, Gordin FM.  Nosocomial outbreak of respiratory tract colonization with Mycobacterium fortuitum: Demonstration of the usefulness of pulsed-field gel electrophoresis in an epidemiologic investigation.  Am. Rev. Respir. Dis.  144:1153-1159, 1991.

  170. Roberts MC, Pang Y, Spencer RC, Winstanley TG, Brown BA, Wallace, RJ Jr:  Tetracycline resistance in Moraxella (Branhamella) catarrhalis - Demonstration of two clonal outbreaks using pulsed-field gel electrophoresis.  Antimicrob. Agents Chemother. 35:2453-2455, 1991.

  171. Wallace RJ Jr., Brown, BA, Tsukamura M, Brown JM, Onyi G:  Clinical and laboratory features of Nocardia nova.  J. Clin. Microbiol.  29:2407-2411, 1991.

  172. McBride ME, Rudolph AH, Tschen JA, Brown BA, Wallace, RJ Jr, Chernoch P, Davis J: Diagnostic and treatment considerations for cutaneous Mycobacterium haemophilum infections.  Arch. Dermatol,  127:276-277, 1991.

  173. Shapiro CL, Haft RF, Gantz NM, Doern GV, Christenson JC, O'Brien R, Overall JC, Brown BA, Wallace RJ Jr:  Tsukamurella paurometabolum:  A novel pathogen causing catheter-related bacteremia in oncology patients.  Rev. Infect. Dis., 1991.

  174. Wallace RJ Jr, Brown BA, Onyi G: Susceptibilities of Mycobacterium fortuitum biovar, fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxin, and amoxicillin-clavulanic acid.  Antimicrob. Agents Chemother.  35:773-775, 1991.

  175. Steingrube VA, Wallace RJ Jr, Brown BA, Zeluff B, Steele LC, Zhang Y:  Acquired resistance to clavulanic acid in Nocardia brasiliensis related to a change in b-lactamase. Antimicrob. Agents Chemother.  35:524-528, 1991.

  176. Wallace RJ Jr, Nash DR, Silcox VA, Tsukamura M, Brown BA, Steele LC, Steingrube VA, Smith JM, Sumter G, Zhang Y, Blacklock Z: Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J. Infect. Dis.  163:598-603, 1991.

  177. Wallace RJ Jr, Tsukamura M, Brown BA, Brown J, Steingrube VA, Zhang Y, Nash DR.  Cefotaxime-resistant Nocardia asteroides strains are isolates of the controversial species Nocardia farcinica.  J. Clin. Microbiol.  28:2726-2732, 1990.

  178. Roberts MC, Brown BA, Steingrube VA, Wallace RJ Jr: Genetic basis of tetracycline resistance in Moraxella (Branhamella) catarrhalis.  Antimicrob. Agents Chemother. 34:1816-1818, 1990.

  179. Wallace RJ Jr, Bedsole G, Sumter G, Sanders CV, Steele LC, Brown BA, Smith J, Graham DR:  Activities of ciprofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single drug therapy. Antimicrob. Agents Chemother. 34:65-70, 1990.

  180. Brown BA, Wallace RJ Jr, Flanagan CW, Wilson RW, Luman JI, Reddit SD, Swenson J:  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.  Antimicrob. Agents Chemother. 33:1631-1633, 1989.

  181. Wallace RJ Jr, Steingrube VA, Nash DR, Hollis D, Flanagan C, Brown BA, Labidi A, Weaver R:  BRO b-lactamases of Branhamella catarrhalis and subgenus Moraxella, including evidence for chromosomal b-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.  Antimicrob. Agents Chemother. 33:1845-1854, 1989.

  182. Wallace RJ Jr, Steele LC, Labidi A, Silcox VA:  Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammaplasty despite case clustering in Texas and other southern coastal states. J. Infect. Dis. 160:281-288, August, 1989.

  183. Wallace RJ Jr: The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae.  Clinics Chest Med. 10:419-429, 1989.

  184. Udou T, Mizuguchi Y, Wallace RJ Jr:  Does aminoglycoside-acetyltransferase in rapidly growing mycobacteria have a metabolic function in addition to aminoglycoside inactivation?  FEMS Microbiol. Letters 57:227-230, 1989.

  185. Nelson BR, Rapini RP, Wallace RJ Jr, Tschen JA: Disseminated Mycobacterium chelonae ssp. abscessus in an immunocompetent host and with a known portal of entry.  J. Am. Acad. Dermatol. 20:909-912, 1989.

  186. Wallace RJ Jr, Musser JM, Hull SI, Silcox VA, Steele LC, Forrester GD, Labidi A, Selander RK: Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac bypass surgery.  J. Infect. Dis. 159:708-716, April, 1989.

  187. Wright PW, Wallace RJ Jr:  Pneumonia due to Moraxella (Branhamella) catarrhalis.  Semin. Respir. Infect .  4:40-46, March, 1989.

  188. Wallace RJ Jr, Steele LC, Sumter G, Smith JM:  Antimicrobial susceptibility patterns of Nocardia asteroides.  Antimicrob. Agents Chemother. 32:1776-1779, December 1988.

  189. Lowry PW, Jarvis WR, Oberle AD, Bland LA, Silberman R, Bocchini JA Jr, Dean HD, Swenson JM, Wallace RJ Jr: Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice.  N. Engl. J. Med. 319:978-982, October 1988.

  190. Wallace RJ Jr, Nash DR, Tsukamura M, Blackock ZM, Silcox VA: Human disease due to Mycobacterium smegmatis.  J. Infect. Dis. 158:52-59, July 1988.

  191. Griffith DE, Wallace RJ Jr: Pulmonary disease due to rapidly growing mycobacteria.  Semin. Respir. Infect.  9:505-513, July 1988.

  192. Wallace RJ Jr, Steele LC, Brooks DL, Forrester GD, Garcia JGN, Luman JI, Wilson RW, Shepherd S, McLarty J: Ampicillin, tetracycline, and chloramphenicol resistant Haemophilus influenzae in adults with chronic lung disease.  Am. Rev. Respir. Dis. 132:695-699, 1988.

  193. Wallace RJ Jr, Steele LC: Susceptibility testing of Nocardia species for the clinical laboratory. Diagn. Microbiol. Infect. Dis.  9:155-166, 1988.

  194. Wallace RJ Jr: Newer oral antimicrobials and newer etiologic agents of acute bronchitis and acute exacerbations of chronic bronchitis.  Semin. Respir. Infect.  3:49-54, March 1988.

  195. Griffith DE, Wallace RJ Jr: Bacterial pneumonia in the adult: Diagnosis and therapy. Hosp. Med. 24:188-203, January 1988.

  196. Wallace RJ Jr, Nash DR, Johnson WK, Steele LC, Steingrube VA: β-lactam resistance in Nocardia brasiliensis is mediated by β-lactamase and reversed in the presence of clavulanic acid.  J. Infect. Dis. 156:959-966, December 1987.

  197. Wallace RJ Jr: Nontuberculous mycobacteria and water - A love affair with increasing clinical importance.  Infect. Dis. Clinics North America 1:677-686, September 1987.

  198. Udou T, Mizuguchi Y, Wallace RJ Jr: Patterns and distribution of aminoglycoside- acetylating enzymes in rapidly growing mycobacteria.   Am. Rev. Respir. Dis. 136:338-343, 1987.

  199. Wallace RJ Jr: Recent clinical advances in knowledge of the non-leprous environmental mycobacteria responsible for cutaneous disease. Arch. Dermatol. 123:337-339, March 1987..

  200. Steele LC, Wallace RJ Jr: Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.  J. Clin. Microbiol. 25:456-457, February 1987.

  201. Ahn CH, Wallace RJ Jr, Steele LC, Murphy DT: Sulfonamide containing regimens for disease caused by rifampin resistant Mycobacterium kansasii.  Am. Rev. Respir. Dis. 135:10-16, 1987.

  202. Wallace RJ Jr: Diagnostic and therapeutic consideration in patients with pulmonary disease due to rapidly growing mycobacteria.  Semin. Respir. Infect. 1:230-233, December 1986.

  203. Nash DR, Wallace RJ Jr, Steingrube VA, Udou T, Steele LC, Forrester GD: Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility.  Am. Rev. Respir. Dis. 134:1276-1282, 1986.

  204. Wallace RJ Jr, Nash DR, Steele LC, Steingrube VA:  Susceptibility testing of slowly growing mycobacteria microdilution MIC method with 7H9 broth. J. Clin. Microbiol. 24:976-981, December 1986.

  205. Luman I, Wilson RW, Wallace RJ Jr, Nash DR: Disk diffusion susceptibility of Branhamella catarrhalis and relationship of β-lactam zone size to β-lactamase production.  Antimicrob. Agents Chemother. 30:774-776, November 1986.

  206. Wallace RJ Jr, Musher DM: In honor of Dr. Sarah Branham, A star is born: The realization of Branhamella catarrhalis as a respiratory pathogen.  Chest 90:447-450, September 1986.

  207. Jonsson S, Wallace RJ Jr, Musher DM, Hull SI: Recurrent Nocardia pneumonia in an adult with chronic granulomatous disease.  Am. Rev. Respir. Dis. 133:932-934, 1986.

  208. Pollard JA, Wallace RJ Jr, Nash DR, Luman JI, Wilson RW: Incidence of Branhamella catarrhalis in the sputa of patients with chronic lung disease.  Drugs 31 (Suppl.3):102-107, 1986.

  209. Nash DR, Wallace RJ Jr, Steingrube VA, Shurin P: Isoelectric focusing of β-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States.  Drugs 31 (Suppl. 3): 47-53, 1986.

  210. Nicotra B, Rivera M, Luman I, Wallace RJ Jr: Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease.  Arch. Intern. Med. 146:890-893, May 1986.

  211. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C: Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.  Antimicrob. Agents Chemother. 28:807-811, December 1985..

  212. Nash DR, Wallace RJ Jr: Immunoglobulin E and other immunoglobulins in patients with eosinophilic pleural effusions.  J. Lab. Clin. Med. 106:512-516, November, 1985.

  213. Wallace RJ Jr, Nash DR, Udou T, Steingrube VA, Steele LC, Swenson JM, Silcox VA: Isoelectric focusing of beta-lactamases in Mycobacterium fortuitum: Association of a single enzyme pattern with cefoxitin resistance.  Am. Rev. Respir. Dis. 132:1093-1097, 1985.

  214. Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG: Treatment of non-pulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J. Infect. Dis. 152:500-514, September 1985.

  215. Wallace RJ Jr, Hull SI, Bobey DG, Price KE, Swenson JM, Steele L, Christensen L: Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium chelonei: Evidence based on plasmid analysis, mutational frequencies, and aminoglycoside modifying enzyme assays.  Am. Rev. Respir. Dis. 132:409-416, 1985.

  216. Greenberg SB, Harris D, Giles P, Martin RR, Wallace RJ Jr: Inhibition of Chalamydia trachomatis growth in McCoy, HeLa, and human prostate cells by zinc. Antimicrob. Agents Chemother. 27:953-957, June 1985.

  217. Wallace RJ Jr, Steele LC, Brooks DL, McLarty JW, Luman JI, Wilson RW: Amoxicillin/clavulanic acid (Augmentin) in the treatment of lower respiratory tract infections due to beta-lactamase positive Haemophilus influenzae and Branhamella catarrhalis.  Antimicrob. Agents Chemother. 27:912-915, June, 1985.

  218. Chapman AJ Jr, Musher DM, Jonsson S, Clarridge JF, Wallace RJ Jr: Development of bactericidal antibody during Branhamella catarrhalis infection. J. Infect. Dis. 152:878-882, May 1985.

  219. Wallace RJ Jr, Steele LC, Forrester GD, Swenson JM, Hull SI:  Susceptibilities of Mycobacterium fortuitum biovariant fortuitum and the unnamed third biovariant complex to heavy-metal salts. Antimicrob. Agents Chemother. 26:594-596, October 1984.

  220. Hull SI, Wallace RJ Jr, Bobey DG, Price KE, Goodhines RA, Swenson JM, Silcox VA: Presence of aminoglycoside acetyl transferase and plasmids in Mycobacterium fortuitum: Lack of correlation with intrinsic aminoglycoside resistance.  Am. Rev. Respir. Dis. 129:614-618, 1984.

  221. Carpenter JL, Troxell M, Wallace RJ Jr: Disseminated disease due to Mycobacterium chelonei treated with amikacin and cefoxitin: Absence of killing with either agent and possible role of granulocytes in clinical response.  Arch. Intern. Med. 144:2063-2065, October 1984.

  222. Wallace RJ Jr, Rosenbaum S: Clinical Challenge: Pneumonia and vomiting: A fortuitous association?  J. Respir. Dis.  5:88-94, March 1984.

  223. Jadeja L, Bolivar R, Wallace RJ Jr: Bacteremia caused by a previously unidentified species of rapidly growing mycobacteria: Successful treatment with vancomycin.  Ann. Intern. Med. 99:475-477, October 1983.

  224. Stone MS, Walllace RJ Jr, Swenson JM, Thornsberry C, and Christensen LA: Agar disk elution method for susceptibility testing of Mycobacterium marinum and  Mycobacterium fortuitum complex to sulfonamides and antibiotics.  Antimicrob. Agents Chemother. 24:486-493, October, 1983.

  225. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS: Spectrum of disease due to rapidly growing mycobacteria. Rev. Infect. Dis. 5:657-679, July/August 1983.

  226. Kuritsky JN, Bullen M., Broome CV, Silcox V, Good R, Wallace RJ Jr:  Sternal wound infections and endocarditis due to organisms of the Mycobacterium fortuitum complex: A potential environmental source.  Ann. Intern. Med. 98:938-939, June 1983.

  227. Wallace RJ Jr, Baker CJ, Quinones FJ, Hollis DG, Weaver RE, Wiss K: Nontypable Haemophilus influenzae (Biotype 4) as a neonatal, maternal, and genital pathogen.  Rev. Infect. Dis.  5:123-136, January/February 1983.

  228. Wallace RJ Jr, Wiss K, Curvey R, Vance PH, Steadham J:  Differences among Nocardia spp, in susceptibility to aminoglycosides and beta-lactam antibiotics and their potential use in taxonomy.  Antimicrob. Agents Chemother. 23:19-21, January 1983.

  229. Musher DM, Wallace RJ Jr: Bacteremic infections caused by nontypable Haemophilus influenzae in patients with dysgammaglobulinemia. J. Clin. Microbiol. 17:143-145, January 1983.

  230. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC: Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.  J. Clin. Microbiol. 16:1003-1006, December 1982.

  231. Mills VA, Clearly TG, Frankel L, Miner ME, Wallace RJ Jr, SilvaSosa M: Central nervous system Nocardia infection. Clin. Pediatr. 21: 248-250, April 1982.

  232. Wallace RJ Jr, Wiss K, Bushby MB, Hollowell DC: In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.  Rev. Infect. Dis. 4:326-331, March/April 1982.

  233. Wallace RJ Jr, Septimus EJ, Williams TW Jr, Conklin RH, Satterwhite TK, Bushby MB, Hollowell DC: Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia.  Rev. Infect. Dis.  4:315-325, March/April 1982.

  234. Musher DM, Wallace RJ Jr: Nontypable Haemophilus influenzae definitely pathogenic for man. Arch. Intern. Med. 142:448, March 1982.

  235. Wallace RJ Jr, Niefield SL, Waters S, Waters B, Wiss K, Martin RR, Greenberg SB: Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.  Antimicrob. Agents Chemother. 21:231-235, February 1982.

Book Chapters

  1. Brown-Elliott BA, Cirillo D, Musser K ,Rowlinson M-C.  Susceptibility Test Methods: Mycobacteria, Nocardia, and Other Actinomycetes.  In:  Manual of Clinical Microbiology, 14th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds.   ASM Press, Washington, D.C., 2027, Vol. _; __:___-___. (in press).

  2. Brown-Elliott BA, Harrington SM, Morimoto K, Wallace Jr., RJ.  Mycobacterium:  Clinical and Laboratory Characteristics of Rapidly Growing Mycobacteria.   In:  Manual of Clinical Microbiology, 14th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds. ASM Press, Washington, D.C. 2027, Vol. _; __:___-___. (in press).

  3. Caulfield AJ, Richter E, Brown-Elliott BA, Wengenack NL.  Mycobacterium: Laboratory Characteristics of Slowly Growing Mycobacteria Other than Mycobacterium tuberculosis. In:  Manual of Clinical Microbiology, 14th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds.  ASM Press, Washington, D.C., 2027, Vol 1; __:___-___. (in press).

  4. Brown-Elliott BA, Zelazny A, Conville P.  Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other Aerobic Actinomycetes.  In:  Manual of Clinical Microbiology, 14th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds.  ASM Press, Washington, D.C., 2027, Vol _; __:___-___. (in press).

  5. Brown-Elliott BA, Wallace Jr. RJ.  Infections Caused by Nontuberculous Mycobacteria Other than Mycobacterium avium Complex:  In:  Mandell, Douglas and Bennett’s Principles and Practice of Infectious Disease, 10th Edition, Blaser MJ, Cohen JI, Holland SM, Doi Y, Falsey AR, Garrett WS, Marr KA, Mitre E, Wilson E, eds.  Elsevier, Philadelphia, PA 2026; Vol. 2, 258:3053-3060.

  6. Griffith DE, Brown-Elliott BA, Wallace Jr. RJ.  Antimycobacterial Agents. In:  Mandell, Douglas and Bennett’s Principles and Practice of Infectious Disease, 10th Edition, Bennett JE, Dolin R, and Blaser MJ, ed.  Elsevier, Philadelphia, PA 2026; Vol. 1, 38:499-513.

  7. Khare, R., and Brown-Elliott, B.A.: Culture, identification, and antimicrobial susceptibility testing of pulmonary nontuberculous mycobacteria.  In: Clinics in Chest Medicine, S Kasperbauer, R Thomson, editors. Elsevier, Philadelphia, PA, 44(4):743-755, December 2023.

  8. Brown-Elliott BA, Cirillo D, Musser K, Rowlinson M-C.  Susceptibility Test Methods: Mycobacteria, Nocardia, and Other Actinomycetes.  In:  Manual of Clinical Microbiology, 13th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds.  ASM Press, Washington, D.C., 2023, Vol 2; 79:1548-1579.

  9. Brown-Elliott BA, Harrington SM, Morimoto K, Wallace Jr., RJ.  Mycobacterium:  Clinical and Laboratory Characteristics of Rapidly Growing Mycobacteria.   In:  Manual of Clinical Microbiology, 13th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds. ASM Press, Washington, D.C. 2023, Vol. 1; 33:657-680.

  10. Caulfield AJ, Richter E, Brown-Elliott BA, Wengenack NL.  Mycobacterium: Laboratory Characteristics of Slowly Growing Mycobacteria Other than Mycobacterium tuberculosis. In:  Manual of Clinical Microbiology, 13th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds.  ASM Press, Washington, D.C., 2023, Vol 1, 32:639-656.

  11. Brown-Elliott BA, Zelazny A, Conville P.  Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other Aerobic Actinomycetes”.  In:  Manual of Clinical Microbiology, 13th Edition, KC Carroll, MA Pfaller, JA Karlowsky, AJ McAdam, ML Landry, R Patel, BS Pritt, eds.  ASM Press, Washington, D.C., 2023, Vol 1; 29:560-593.

  12. Brown-Elliott, BA, Salfinger M.  Antimicrobial susceptibility testing for slowing growing nontuberculous mycobacteria. ASM Press 2022. 7.9.2.1  doi: 10.1128/9781555818814.ch7.9.2.

  13. Brown-Elliott BA, Wallace RJ Jr.:  Infections caused by nontuberculous mycobacteria other than Mycobacterium avium complex.  In:  Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease, 9th Edition, Bennett JE, Dolin R, and Blaser MJ ed.  Elselvier, Philadelphia, PA. 2019, Vol. 2, 252:3049-3058.

  14. Woods GL, Brown-Elliott BA, Lin S-YG, Desmond EP: Susceptibility test methods:  Mycobacteria, Nocardia, and other actinomycetes. In: Manual of Clinical Microbiology, 12th Edition, KC Carroll, ed. ASM Press, Washington, D.C. 2019, Vol. 2, 78:1398-1419.

  15. Brown-Elliott BA, Wallace RJ Jr.:  Mycobacterium:  Clinical and laboratory characteristics of rapidly growing mycobacteria.  In:  Manual of Clinical Microbiology, 12th Edition, KC Carroll, ed. ASM Press, Washington, D.C.  2019, Vol. 1; 34:612-629.

  16. Caulfield AJ, Richter E, Brown-Elliott BA, Wallace RJ Jr., Wengenack NL: Mycobacterium: Laboratory characteristics of slowly growing mycobacteria other than Mycobacterium tuberculosis. In: Manual of Clinical Microbiology, 12th Edition, J. KC Carroll, ed. ASM Press, Washington, D.C. 2019, Vol. 1, 33:595-611.

  17. Conville P, Brown-Elliott BA, Witebsky, FG:  Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces and other Actinomycetes.  In:  Manual of Clinical Microbiology, 12th Edition, KC Carroll, ed.  ASM Press, Washington, D.C.  2019, Vol. 1, 30:525-557.

  18. Brown-Elliott BA, Wallace Jr., RJ:  Healthcare-associated outbreaks and pseudo-outbreaks of nontuberculous mycobacteria.  In:  Nontuberculous Mycobacterial Disease, D.E. Griffith, ed. Humana Press, Switzerland, pp. 483-503, 2018.

  19. Brown-Elliott BA:  Laboratory diagnosis and antimicrobial susceptibility testing of nontuberculous mycobacteria.  In:  Nontuberculous Mycobacterial Disease, D.E. Griffith, ed. Humana Press, Switzerland, pp. 15-59, 2018.

  20. Brown-Elliott BA, Wallace RJ Jr.:  Mycobacterium:  Clinical and laboratory characteristics of rapidly growing mycobacteria.  In:  Manual of Clinical Microbiology, 11th Edition, J. Versalovic, ed. ASM Press, Washington, D.C.  2015, Vol. 1, 32:595-612.

  21. Simner PJ, Stenger S, Richter E, Brown-Elliott BA, Wallace Jr. RJ, Wengenack NL: Mycobacterium:  Laboratory characteristics of slowly growing mycobacteria.  In:  Manual of Clinical Microbiology, 11th Edition, J. Versalovic, ed.  ASM Press, Washington, D.C.  2015, Vol. 1, 31:570-594.

  22. Brown-Elliott BA, Wallace RJ Jr.:  Infections caused by nontuberculous mycobacteria other than Mycobacterium avium complex.  In:  Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease, 8th Edition, Bennett JE, Dolin R, and Blaser MJ ed.  Elselvier Saunders, Philadelphia, PA. 2015, Vol. 2, 254:2844-2852.

  23. Brown-Elliott BA, Wallace RJ Jr:  Nontuberculous mycobacteria.  In:  Hospital Epidemiology and Infection Control, 4th Edition, C.G. Mayhall, ed.  Lippincott Williams & Wilkins.  2012; 39:593-608.

  24. Brown-Elliott BA, Wallace RJ Jr:  Rapidly growing mycobacteria.  In:  Tuberculosis & Nontuberculous Mycobacterial Infections, 6th edition, D Schlossberg, ed.  ASM Press, Washington, D.C.  2011, pp. 565-577.

  25. Richter E, Brown-Elliott BA, Wallace RJ Jr.:  Mycobacterium:  Laboratory characteristics of slowly growing mycobacteria.  In:  Manual of Clinical Microbiology, 10th Edition, J. Versalovic, ed.  ASM Press, Washington, D.C.  2011, Vol. 1, pp. 503-524.

  26. Brown-Elliott BA, Wallace RJ Jr.:  Mycobacterium:  Clinical and Laboratory Characteristics of rapidly growing mycobacteria.  In:  Manual of Clinical Microbiology, 10th Edition, J. Versalovic, ed.  ASM Press, Washington, D.C.  2011, Vol. 1, pp. 525-538.

  27. Brown-Elliott BA, Wallace RJ Jr:  Infections due to nontuberculous mycobacteria other than Mycobacterium avium-intracellulare.  In:  Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Seventh Edition, Mandell, Bennett, Dolin, eds, Elsevier Churchill Livingstone Inc., 2010, Vol. 2, 253: 3191-3198.

  28. Brown-Elliott, BA, Cohen, S, Wallace RJ Jr.:  Susceptibility testing of mycobacteria.  In:  Antimicrobial Susceptibility Testing Protocols, R Schwalbe, L Steele-Moore, AC Goodwin, eds.  CRC Press, Boca Raton, FL.  11:243-274, 2007.

  29. Brown-Elliott BA, Wallace RJ Jr.:  Mycobacterium:  Clinical and Laboratory Characteristics of Rapidly Growing Mycobacteria.  In:  Manual of Clinical Microbiology, 9th Edition, P.R. Murray, ed. ASM Press, Washington, D.C.  Vol. 1, 38:589-600, 2007.

  30. Brown-Elliott BA, Wallace RJ Jr:  Rapidly growing mycobacteria.  In:  Tuberculosis & Nontuberculous Mycobacterial Infections, 5th edition, D Schlossberg, ed.  McGraw-Hill Companies, Inc., 35:451-462, 2006.

  31. Brown-Elliott BA, Wallace RJ Jr: Infections caused by nontuberculous mycobacteria.  In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Sixth Edition, Mandell, Bennett, Dolin, eds, Elsevier Churchill Livingstone Inc., Vol. 2, 251:2909-2916, 2005.

  32. Brown-Elliott BA:  Micobacterias no tuberculosas recientemente identificadas en humanos.  Salud i Ciencia (SIIC).  P. 6-9, 2004 (www.siicsalud.com).

  33. Vincent V, Brown-Elliott BA, Jost KC Jr, Wallace RJ Jr: Mycobacterium: Phenotypic and genotypic identification.  In:  Manual of Clinical Microbiology, 8th edition, Vol. 1, PR Murray, ed. ASM Press, Washington, DC,  37:560-584, 2003.

  34. Pfyffer GE, Brown-Elliott BA, Wallace RJ Jr:  Mycobacterium: General characteristics, isolation and staining procedures.  In:  Manual of Clinical Microbiology, 8th edition, Patrick R. Murray, ed.  ASM Press, Washington, DC, 36:532-559, 2003.

  35. Griffith, D.E., Brown-Elliott, B.A., and Wallace, R.J. Jr: Diagnosing nontuberculous mycobacterial lung disease.  In: Infectious Disease Clinics of North America, C. Davis, ed., W.B. Saunders Company, Philadelphia, PA.  16:235-249, 2002.

  36. Brown-Elliott, B.A., Griffith, D.E., and Wallace, R.J. Jr: Newly described or emerging human species of nontuberculous mycobacteria.  In: Infectious Disease Clinics of North America, C. Davis, ed., W.B. Saunders Company, Philadelphia, PA.  16:187-219, 2002.

  37. Wallace RJ Jr, Brown-Elliott BA, Griffith DE: Nontuberculous mycobacteria.  In:  Respiratory Infections, Second Edition, MS Niederman, GA Sarosi, J Glassroth eds., Lippincott Williams & Wilkins, Philadelphia.  38:487-500, 2001.

  38. Brown BA, Wallace RJ Jr: Nocardia farcinica: Un agente involucrado en infecciones nosocomiales y adquiridas en la comunidad.  In: Infección 2001, E. Bozua, J.J. Picazo, eds, Servisistem S.L. pp. 197-212, 2000.

  39. Brown BA, Wallace RJ Jr: Infections due to nontuberculous mycobacteria.  In: Mandel, Douglas and Bennett's Principles and Practice of Infectious Diseases, Fifth Edition, Mandell, Bennett, Dolin, eds, Churchill Livingstone Inc., Vol. 2, 243:2630-2636, 2000.

  40. Wallace RJ Jr, Brown BA: Mycobacterium fortuitum, chelonae, abscessus.  In: Tuberculosis and Nontuberculous Mycobacterial Infections, David Schlossberg, ed., W.B. Saunders Co, p. 372-379, 1999.

  41. Wallace, R.J. Jr, Brown, B.A., Stocks, J.M., Griffith, D.E., Mazurek, G.H., Luman, J.I., Wilson, R.W., and Redditt, S.D.:  Comparison of cefixime and amoxicillin/clavulanic acid in LRTI.  In:  Infections in Medicine, Antimicrobial Therapy, p. 16-29, 1993.

  42. Brown BA, Swenson JM, Wallace RJ Jr.  Broth Microdilution MIC Test for Rapidly Growing Mycobacteria.  In: Clinical Microbiology Procedures Handbook, Section 5: Antimicrobial Susceptibility Testing, p. 5.11.  American Society for Microbiology Book Division, Washington, DC.  1992.

  43. Brown BA, Swenson JM, Wallace RJ Jr.  Agar Disk Elution Test for Rapidly Growing Mycobacteria.  In: Clinical Microbiology Procedures Handbook, Section 5: Antimicrobial Susceptibility Testing, p. 5.10.  American Society for Microbiology Book Division, Washington, DC.  1992.

  44. Hawkins JE, Wallace RJ Jr, Bron BA: Antibacterial Susceptibility Tests: Mycobacteria.  In: Manual of Clinical Microbiology, Fifth Edition.  American Society for Microbiology, Albert Balows, editor, pp. 1138-1152, 1990.

  45. Wallace RJ Jr: Infections caused by actinomycetes. In : Textbook of Internal Medicine. W. Kelley (ed.), J. B.  Lippincott Company publishers, Vol. 2, 292: 1598-1601, 1989.

  46. Griffith DE, Wallace RJ Jr: Environmental mycobacterial diseases. In: Textbook of Internal Medicine. W. Kelley (ed.), J. B. Lippincott Company publishers, Vol. 2, 286:1578-1582, 1989.

  47. Wright PW, Wallace RJ Jr: Bone and joint tuberculosis. In: Monograph on Orthopedic Infections.  Robert D'Ambrosia and Robert L. Marier (editors), Slack Incorporated publishers, pages 267-282, 1989.

  48. Rivera M, Nicotra MB, Wallace RJ Jr: Thoracic actinomycosis. In: Current Therapy in Internal Medicine - 2. TM Bayless, MC Brain, RM Cherniack, editors. (BC Decker, Toronto/Philedelphia, publishers), pages 775-777, 1987.

  49. Musher DM, Wallace RJ Jr: Treatment of infections due to Haemophilus influenzae.  In: The Antimicrobial Agents Annual/2. PK Peterson and J Verhoef, editors.  Elsevier Science Publishers, New York, pages 383-391, 1987.

  50. Septimus EJ, Wallace RJ Jr: Nocardial Infection. In: Current Therapy in Infectious Disease - 2 by E.H. Kass and R. Platt, B.C. Decker Inc, Philadelphia/Toronto, publisher, pages 356-357, 1986.

  51. Rivera M, Nicotra MB, Wallace RJ Jr: Thoracic actinomycosis.  In: Current Therapy of Respiratory Disease -2 by  Cherniack, B.C. Decker Inc, Philadelphia/ Toronto, publisher, pages 53-55, 1986.

  52. Wallace RJ Jr, Austin JH: The patient with an infection of the skin and soft tissues. In: Infectious Diseases of Children and Adults,HL Dupont ,L Pickering, (eds.), Addison-Wesley Publishing Co. Inc, 8:138-166, 1986.

Invited Reviews and Editorials

  1. Brown-Elliott BA, Falkinham JO, Furlong JL, Griffith DE, Musser KA, Parrish NM, Salfinger M, Stout JE, Wengenack NL, Zelazny AM.  Laboratory diagnosis of nontuberculous mycobacteria – an update – Part 3: Molecular diagnostics, environmental testing, and notifiable conditions. Clin. Microbiol. Newsl.  52(C):50-60, September 2025.

  2. Brown-Elliott BA, Falkinham JO, Furlong JL, Griffith DE, Musser KA, Parrish NM, Salfinger M, Stout JE, Wengenack NL, Zelazny AM.  Laboratory diagnosis of nontuberculous mycobacteria – an update – Part 2: Specimen collection and laboratory work-up. Clin. Microbiol. Newsl. 52(C):62-75, September 2025.

  3. Brown-Elliott BA, Falkinham JO, Furlong JL, Griffith DE, Musser KA, Parrish NM, Salfinger M, Stout JE, Wengenack NL, Zelazny AM:  Laboratory diagnosis of nontuberculous mycobacteria – an update – Part 1: Epidemiology, environment sources, and guidance for the provider. Clin. Microbiol. Newsl. 2025; 52(C):31-43, September 2025.

  4. Brown-Elliott BA, Eagle G, Wallace RJ, van Ingen J, Pennings LJ, Berry B, Pandley S, Coulter C. Syrmis M, Winthrop KL, Griffith DE:  Amikacin liposome inhalation suspension (ALIS) add-on therapy for refractory Mycobacterium avium complex (MAC) lung disease:  Effect of in vitro amikacin susceptibility on sputum culture conversion.  Open Forum Infect. Dis.  5(Suppl 1):S288-S289. November 2018.

  5. Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Cardoso-Leão S, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, Philley JV, Niemann S, Wallace Jr. RJ, Cirillo DM:  Mycobacterium abscessus, a taxonomic puzzle.  Letter to the Editor.  Int. J. Syst. Evol. Microbiol.  2018; 68:467-469.

  6. Brown-Elliott BA, Philley J:  Rapidly growing mycobacteria.  Microbiol Spectrum 5(1):TNM17-0027-2016, 2017.

  7. Brown-Elliott BA, Philley JV, Benwill JL, Wallace RJ Jr:  Current opinions in the treatment of pulmonary nontuberculous mycobacteria in non-cystic fibrosis patients: Mycobacterium abscessus group, Mycobacterium avium complex, and Mycobacterium kansasii.  Cur Treat Opt Infect Dis.  2014; DOI10:1007/s40506-014-0032-2 published online.

  8. Aitken ML, Cangelosi GA, Brown-Elliott BA, Dirac MA, Olivier KN, Limaye A: Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am. J. Resp. Crit Care Med. 185(2):231-232, 2012.

  9. Huth RG, Brown-Elliott BA, Wallace RJ Jr: Mycobacterium mageritense pulmonary disease in an immunocompromised host.  Letter to the Editor.  Emerg. Infect. Dis.  17:556-558, 2011.

  10. Witebsky FG, Conville PS, Wallace RJ Jr., Brown-Elliott BA:  Nocardia cyriacigeorgica – an established rather than an emerging pathogen.  J. Clin. Microbiol.  46:2469-2470, 2008.

  11. Brown-Elliott, B. A.:  Clinical and laboratory diagnosis and susceptibility testing of Nocardia.  SWACM Newsletter.  9(2):11-12, 2005.

  12. Brown-Elliott BA, Wallace RJ Jr: Clarithromycin resistance in Mycobacterium abscessus.  Letter to the Editor.  J. Clin. Microbiol.  39:2745-2746, 2001.

  13. Wallace RJ Jr, Brown BA, Griffith DE: Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria.  Annu. Rev. Microbiol.  52:453-490, 1998.

  14. Wallace RJ Jr, Brown BA: Catheter sepsis due to Mycobacterium chelonae.  Letter to the Editor.  J. Clin. Microbiol.  36:3444-3445, 1998.

  15. Wallace RJ Jr, Brown BA, Steingrube VA, Wilson R: Request for clarification of the difference between M. mageritense sp. nov. and M. smegmatis.  Intern. J. Syst. Bacteriol.  47:1277-1278. 1997.

  16. Wallace RJ Jr., Brown BA, Griffith DE: Mycobacterium chelonae vs. abscessus.  Ped. Infect. Dis. J.; 16:829, 1997.

  17. Wallace RJ Jr, Griffith DE, Brown BA, Girard WM: Response to Letter to the Editor by Richard Frothingham on “Clarithromycin treatment for Mycobacterium avium-intracellulare complex lung disease.”  Amer. J. Respir.  Crit. Care Med. 153:1990-1991, 1996.

  18. Steingrube VA, Gibson JL, Brown BA, Zhang Y, Wilson RW, Rajagopalan M, Wallace RJ Jr: ERRATUM. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria.  J. Clin. Microbiol.  33:1686, 1995.

  19. Brown BA, Wallace RJ Jr:  Cutaneous disease caused by a rapidly growing mycobacterium.  Amer. Soc. Clin. Pathol. 38:61-77, 1995.

  20. Wallace RJ Jr, Brown BA, Brown JM, McNeil M:  Taxonomy of Nocardia Species.  Clin. Infect. Dis.; 18:476, 1994.

  21. Wallace RJ Jr, Silcox, V, Brown BA:  Taxonomy of Rapidly Growing Mycobacteria.  Clin. Infect. Dis., 18:121-122, 1994.

  22. Brown BA, Roberts MC, Wallace RJ Jr.  Emergence of Antimicrobial Resistance in Moraxella (Branhamella) Catarrhalis.  In: The Alliance for the Prudent Use of Antibiotics Newsletter, p. 3.  Fall 1990.

  23. Dorn, G.L., Brown, B.A., Cohen, R.L., Moore, J.A., Barlow, J.F., Southern, P.M. Jr., Ketchum, K., and Leonard, J.S.:  Adherence to laboratory guidelines:  a study on urine specimen transit time.  Diagnostics and Clinical Testing.  Vol, 27, 1989.

  24. Wallace RJ Jr: Letter to the editor. Therapeutic failure due to Branhamella catarrhalis in pneumococcal pneumonia.  Chest  92:382-383, August 1987.

  25. Wallace RJ Jr, Swenson JM, Silcox VA: The rapidly growing mycobacteria: Characterization and susceptibility testing.  The Antimicrobic Newsletter 2:85-92, December 1985.

  26. Brown, B.A:  Herpes Simplex Virus Isolation.  Diagnostic Reference Laboratories, Inc. Bulletin, Nov./Dec. 1985.

  27. Brown, B.A:  Effects of Exercise on Common Laboratory Tests.  Diagnostic Reference Laboratories, Inc. Bulletin, 1985.

  28. Wallace RJ Jr: Nontuberculous, nonleprous mycobacterioses.  Infect. Dis. Newsletter, 4(7):49-56, July 1985.

  29. Wallace RJ Jr, Good RC, Swenson JM, Silcox VA: Chest communications to the Editor - Multidrug resistance in Mycobacterium fortuitum.  Chest 87:275-276, February 1985.

  30. Wallace RJ Jr: The increasing role of beta-lactamase producing organisms as causative agents of respiratory tract disease: The decline and fall of penicillin?  Postgraduate Medicine Supplement: Custom Communications Special Report, p. 121-128, September/October 1984.

  31. Wallace RJ Jr: (Another) new technique for an old disease: The protected brush catheter and bacterial pneumonia.  Chest  81:532-533, May 1982.

Abstracts

  1. Kang, C. J., Kathman, D., Newstein, M.C., Somayaji, K.C., Rodriguez, E. M., Manchikalapudi, A. L., Botkin, K. M., Kumaraswamy, M., Brown-Elliott, B. A. (2026).  Discordant Clarithromycin Susceptibility Across Two Mycobacterium avium  Colony Morphotypes from a Single Culture.  Chest Annual Meeting, Phoenix, AZ, October 18-21, 2026, Abstract #.

  2. Wallace, R.J., McShane, P.J., Brown-Elliott, B.A., Griffith, D.E., Khare, R., Kumaraswamy, M., Daley, C., Kasperbauer, S., & Alexander, D. C. (2025). Proposed Tentative Susceptible and Resistant Breakpoints for Bedaquiline with Mycobacterium avium complex (MAC). Colorado Mycobacteria Conference 2025: Nontuberculous Mycobacteria, May 27-30, 2025, Abstract 33.

  3. Wallace, R. J., Brown-Elliott, B. A., Kumaraswamy, M., Botkin, K., Bush, G., Esiesimua, B., Gonzalez-Ramirez, B., Hughes, M. D., Manchikalapudi, V., Melton, S., Rodriguez, E., Somayaji, K., Turenne, C. Y., Graham, C. I., Soualhine, H., Stobart, M., Honda, J. R., & Alexander, D. C. (2025). A New Taxon of Rapidly Growing Mycobacteria with Plasmid-Mediated Macrolide Resistance. ASM Microbe 2025.

  4. Jackson KA, Hernandez-Romieu AC, Barter D, Czaja CA, Johnston H, Lynfield R, Tourdot L, Snippes-Vagnone P, Walters J, Dumyati G, Escutia G, Pierce RA, Brown-Elliott B, Salfinger M, Winthrop K, Toney NC, Magill SS, Grigg C:  Feasibility assessment of population-based nontuberculous mycobacteria surveillance at four emerging infections program sites. 2022 CSTE Annual Conference, Louisville, KY, June 19-23, 2022, Abstract 15548.

  5. Azim AA, Gordon P, Connors B, Wallace R, Brown-Elliott BA, Mehrotra P, Wright SB:  Mycobacterium abscessus surgical site infections due to modular cooler heater units in cardiac surgery. Shea 2021, Abstract 134.

  6. McShane P, Philley J, Iakhiaeva E, Brown-Elliott B, Sigler C, Vasireddy S, Griffith D, Wallace RJ.  Clinical findings and molecular identification of respiratory isolates of pulmonary Mycobacterium chimaera in the United States.  Chest Annual Meeting, October 18-21, 2020.

  7. Winthrop KL, Flume PA, Thomson R, Brown-Elliott BA, Wallace Jr., RJ, Griffith DE, Pennings LJ, Coulter C, Syrmis M, Pandey S, Yuen D, Mange K, van Ingen J:  Amikacin liposome inhalation suspension (ALIS) for treatment-refractory Mycobacterium avium complex (MAC) lung disease: Effect of baseline amikacin and clarithromycin susceptibility on culture conversion.  ATS 2020 International Conference, Philadelphia, PA, May 15-20, 2020, Abstract.

  8. Davidson RM, Benoit JB, Kammlade SM, Hasan NA, Epperson LE, Vasireddy S, Smith T, Brown-Elliott BA, Nick JA, Olivier K, Zelazny A, Daley CL, Strong M, Wallace Jr., RJ:  Genomic characterization of sporadic isolates of the dominant circulating clone of Mycobacterium abscessus subspecies massiliense in the United States.  North American Cystic Fibrosis Conference, 2019.

  9. Almodovar A, Ritter K, Shipp K, Smith T, Vasireddy S, Wallace Jr. RJ, Brown-Elliott BA:  Case Report: Patient with pulmonary fibrosis associated with M. abscessus subsp. massiliense. Southern Coast Mycobacterial Workshop, October 19-20, 2018, Lafayette, LA, Poster.

  10. Kammlade SM, Nick SE, Rodger RR, Epperson LE, Hasan NA, Strong M, Daley CL, Nick JA, Vasireddy S, Brown-Elliott BA, Wallace Jr., RJ, Salfinger M, Davidson RM:  Prevalence of drug resistance mutations in nontuberculous mycobacteria isolates from CF patients in the U.S. North American Cystic Fibrosis Conference, October 2018.

  11. Griffith DE, Eagle G, Wallace Jr., RJ, Brown-Elliott BA, van Ingen J, Pennings LJ, Berry B, Pandey S, Coulter C, Syrmis M, Morimoto K, Hasegawa N, Winthrop KL: Relationship between in vitro clarithromycin susceptibility and sputum culture conversion with add-on amikacin liposome inhalation Suspension (ALIS) for treatment of refractory Mycobacterium avium complex (MAC) lung disease.  Chest, October 6-10, 2018, San Antonio, TX.

  12. Brown-Elliott BA, Eagle G, Wallace Jr., RJ, van Ingen J, Pennings LJ, Berry B, Pandey S, Coulter C, Syrmis M, Winthrop KL, Griffith DE: Amikacin liposome inhalation suspension (ALIS) add-on therapy for refractory Mycobacterium avium complex (MAC) lung disease: Effect of in vitro amikacin susceptibility on sputum culture conversion.  IDWeek, October 3-7, 2018, San Francisco, CA.  Abstract # 73099, poster 805.

  13. Brown-Elliott BA, Ashcraft M, Bush G, McKinney A, Ritter K, Shipp K, Wallace Jr. RJ, Rubio A:  In vitro characterization of a novel gyrase inhibitor (Spr719) against nontuberculous mycobacteria. ASM Microbe 2018, June 7-11, 2018, Atlanta, GA. Poster # 538.

  14. Philley JV, Calhoun KM, Thakkar FM, Brown-Elliott BA, Wallace Jr. RJ, Griffith DE:  Macrolide resistant Mycobacterium avium complex pulmonary disease treated with bedaquiline.  ATS 2018 International Conference, San Diego, CA, May 18-23, 2018.

  15. Olivier KN, Griffith DE, Winthrop KL, Brown-Elliott BA, Eagle G, McGinnis II JP, Wallace Jr. RJ:  12-month follow-up data from a phase 2 trial of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacteria (NTM) lung infection.  World Bronchiectasis Conference, July 7-9, 2016, Hannover, Germany.

  16. Brown-Elliott BA, Philley JV, Griffith DE, Wallace Jr. RJ:  Comparison of in vitro susceptibility testing of tedizolid (TZD) and linezolid (LZD) against isolates of nontuberculous mycobacteria (NTM).  ASM Microbe 2016, June 16-20, 2016, Boston, MA. Abstract  #458.

  17. Brown-Elliott BA, Wallace Jr. RJ:  Comparison of in vitro susceptibility testing of tedizolid (TZD) and linezolid (LZD) against isolates of Nocardia.  ASM Microbe 2016, June 16-20, 2016, Boston, MA. Abstract  #465.

  18. Olivier KN, Griffith DE, Winthrop KL, Brown-Elliott BA, Eagle G, McGinnis II JP, Wallace Jr. RJ:  12-month follow-up data from a phase 2 trial of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung infection.  ATS 2016 International Conference, May 13-18, 2016, San Francisco, CA, Abstract #11396.

  19. Olivier KN, Eagle G, McGinnis JP II, Micioni L, Brown-Elliott BA, Wallace Jr. RJ:  Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI).  ERS 2015, 25th Annual Congress of the European Respiratory Society, September 26-30, 2015, Amsterdam, Netherlands, Abstract #PA371.

  20. Olivier KN, Eagle G, McGinnis JP II, Micioni L, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, Salathe M, Brown-Elliott BA, Wallace RJ, Griffith DE: Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with recalcitrant nontuberculous mycobacterial (NTM) lung disease (LD).  European Cystic Fibrosis Society 2015 Conference (previously presented at NACFC 2014), June 10-13, 2015, Brussels, Belgium, Abstract #WS02.3.

  21. Branda JA, Brown-Elliott BA, Wallace Jr. RJ, Olson B, Alame D, Vasireddy R, Vasireddy S, Fritsche TR:  Head-to-head comparison between commercially-available MALDI-TOF mass spectrometry systems for the identification of nontuberculous mycobacteria.  115th General Meeting of the American Society for Microbiology, New Orleans, LA,  May 30-June 2, 2015, Abstract #1996.

  22. Biller JA, Eagle G, McGinnis II JP, Micioni L, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, Salathe M, Brown-Elliott BA, Wallace Jr., RJ, Griffith DE, Olivier KN: Efficacy of liposomal amikacin for inhalation (LAI) in achieving negative sputum cultures for nontuberculous mycobacteria (NTM) in patients whose lung infection is refractory to guideline-based therapy.  ATS 2015 International Conference, May 15-20, 2015, Denver, CO, poster #611.

  23. Winthrop KL, Eagle G, McGinnis II JP, Micioni L, Daley CL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, Salathe M, Brown-Elliott BA, Wallace Jr., RJ, Griffith DE, Olivier KN: Subgroup analyses of baseline demographics and efficacy in patients with refractory nontuberculous mycobacteria (NTM) lung infection treated with liposomal amikacin for inhalation (LAI).  ATS 2015 International Conference, May 15-20, 2015, Denver, CO, poster #610.

  24. Olivier KN, Gupta r, Eagle G, McGinnis JP II, Micioni L, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, Salathe M, Brown-Elliott BA, Wallace RJ, Griffith DE: Randomized, double-blind, placebo-controlled study and open-label extension of liposomal amikacin for inhalation (LAI in patients with recalcitrant nontuberculous mycobacterial lung disease (NTM-LD).  2014  American Cystic Fibrosis Conference, Atlanta, GA, October 9-11, 2014, Poster #293.

  25. Philley, J, Guthrie C, Whitehead S, McClendon S, Drake S, Obayangban T, Cook S, Rosas A, Benwill J, Wallace R, Brown-Elliott B, Dasgupta S, Griffith DE:  A possible association between breast cancer, bronchiectasis and nontuberculous mycobacteria (NTM) lung disease.  European Respiratory Society 2014 International Congress, Munich, Germany, September 6-10, 2014, Abstract #3756.

  26. Griffith DE, Adjemian J, Brown-Elliott BA, Philley J, Prevots DR, Hunsberger S, Gaston C, Oliviver K, Wallace RJ:  The value of semi-quantitative mycobacterial cultures for predicting culture conversion during MAC lung disease therapy.  European Respiratory Society 2014 International Congress, Munich, Germany, September 6-10, 2014, Abstract # P246.

  27. Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Parodi N, Strong A, Gee M, McNulty S, O’Neil S, Wallace Jr. RJ:  Sequencing of erm gene in isolates of Mycobacterium abscessus subspecies abscessus with low clarithromycin MICs.  114th General Meeting of the American Society for Microbiology, Boston, MA,  May 17-20, 2014, Abstract #945.

  28. Philley JV, Iakhieva E, McNulty S, Brown-Elliott BA, Falkinham III JO, Williams MD, Vasireddy R, Vasireddy S, Wilson RW, Griffith DE, Turenne C, Benwill J, Stout JE, Wallace Jr. RJ:  Clinical and laboratory features of respiratory isolates of Mycobacterium chimaera.  ATS 2014 International Conference, San Diego, CA, May 16-21, 2014, Abstract # A4129.

  29. Olivier K, Gupta R, Daley C, Winthrop K, Ruoss S, Addrizzo-Harris D, Flume P, Dorgan D, Salathe M, Brown-Elliott B, Wallace R, Griffith D, for the Arikace in NTM Study Group.  A randomized double-blind, placebo-controlled study of liposomal amikacin for inhalation (Arikace®) in patients with recalcitrant nontuberculous mycobacterial lung disease.  ATS 2014 International Conference, San Diego, CA, May 16-21, 2014, Abstract # A4126.

  30. Benwill JL, Philley JV, Taskar V, Brown-Elliott BA, Griffith DE, Wallace RJ:  Inhaled amikacin for the treatment of pulmonary Mycobacterium avium complex (MAC) infection.  ATS 2014 International Conference, San Diego, CA, May 16-21, 2014, Abstract # A4112.

  31. Fritsche TR, Elliott BA, Wallace RJ Jr., Olson B, Alame D, Vasireddy R, Vasireddy S, Branda J:  Comparative evaluation of two commercially available MALDI-TOF mass spectrometry systems for the rapid and accurate identification of rapidly-growing mycobacteria.  25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, May 10-13, 2014.

  32. Wallace RJ, Philley J, Brown-Elliott BA, McNulty S, Wilson R, Iakhiaeva E:  Mycobacterium avium lung disease and the modern day Broad Street pump.  Institut Pasteur, Paris, France.  October 1-5, 2013.

  33. Iwanaga K, Brown-Elliott BA, Wallace RJ, Carter ER:  Clinical characteristics and outcomes in children infected with Mycobacterium abscessus complex subspecies: A case series.  26th Annual North American Cystic Fibrosis Conference, Orlando, FL, October 11-13, 2012.  Abstract #312.

  34. Deml SM, Klein KR, Wohlfiel  SL, Brown-Elliott BA, Wallace RJ Jr., Wengenack NL:    Evaluation of the Sensititre® SLOMYCO plate for antimicrobial susceptibility testing of slowly growing, nontuberculous mycobacteria.  112th General Meeting of the American Society for Microbiology, San Francisco, CA, June 16-19, 2012, Abstract #1194.

  35. Howard ST, Newman KL, McNulty S, Brown-Elliott BA, Bridge L, Wallace RJ Jr:  Genomic variation in the DNA degradation locus of Mycobacterium abscessus.  112th General Meeting of the American Society for Microbiology, San Francisco, CA, June 16-19, 2012, Abstract# 2671.

  36. Sungkapalee T, Ellison RT 3rd, Brown-Elliott BA, Vasireddy R, Wallace RJ Jr: Persistent Mycobacterium seoulense pulmonary disease.  15th International Congress on Infectious Disease, Bangkok, Thailand, June13-16, 2012, Abstract #47.043.

  37. Wallace RJ Jr., Brown-Elliott BA, Kriel K, Martin T, Bridge L, Vasireddy R:  Comparison of in vitro activity of cetobiproble (BPR) with ceftriaxone (CRO), ceftazidime (TAZ), and cefepime (FEP) against isolates of rapidly growing mycobacteria (RGM) and Nocardia (NOC).  51st ICAAC, Chicago, IL, September 17-20, 2011, Abstract E-118.

  38. Brown-Elliott BA, Kriel K, Martin T, Bridge L, Vasireddy R, Wallace RJ Jr:  Comparison of in vitro activity of doripenem (DOR) with imipenem (IPM), and meropenem (MER) against isolates of rapidly growing mycobacteria (RGM) and Nocardia (NOC).  51st ICAAC, Chicago, IL, September 17-20, 2011, Abstract E-117.

  39. Chen LF, Cook E, Brown-Elliott BA, Lockamy D, Miller BA, Sexton DJ, Mochring RW, Clifford PE, and Anderson DJ:  Fortuitum by name, fortuitus by nature: investigating a potential cluster of Mycobacterium fortuitum prosthetic joint infections.  48th Annual Meeting of the Infectious Disease Society of America, Vancouver, BC, October 21-24, 2010, Abstr. #386.

  40. Brown-Elliott BA, McNulty S, Bridge L, Wallace RJ Jr., Falk P, Mayhall CG, Sarria JC, Loeffelholz M:  Molecular epidemiology and laboratory characteristics of clustered isolates of Mycobacterium porcinum from a University Medical Center.   110th General Meeting of the American Society for Microbiology, San Diego, CA, May 23-27, 2010, Abstract U-470.

  41. Wallace RJ, Brown-Elliott B, McNulty S, Zhang Y, Killingley J, Wilson R, York D, Griffith DE:  Outcome of standard multidrug therapies for nodular/ bronchiectatic (NB) Mycobacterium avium complex (MAC) lung disease.  2010 ATS International Conference, New Orleans, LA, May 14-19, 2010, Abstract # 502, Am J. Respir Crit Care Med 181:2010:A2596.

  42. Pillai PT, Williams MM, O’Connell H, Brown-Elliott BA, McNulty S, McGlasson M, Mann LB, Vasireddy R, Wallace RJ Jr.:  Outbreak of Mycobacterium goodii surgical site infections - Midwest region, 2007-2009.  The 5th Decennial International Conference on Healthcare-Associated Infections, Epidemic Intelligence Service Conference.  Atlanta, GA, April 19-23, 2010, Abstract #19, page 99.

  43. Pillai PT, Williams MM, O’Connell H, Brown-Elliott BA, McNulty S, McGlasson M, Mann LB, Vasireddy R, Wallace RJ Jr.:  Outbreak of Mycobacterium goodii surgical site infections - Midwest region, 2007-2009.   Society for Healthcare Epidemiology of America (SHEA), Atlanta GA, March 18-22, 2010, Abstract #559, page 56.

  44. Wallace RJ, Dukart G, Brown-Elliott BA, Griffith DE, Marshall B:  Experience with tigecycline in infections due to Mycobacterium abscessus complex and Mycobacterium chelonae.  The 19th ECCMID, Helsinki, Finland, May 16-19, 2009.  Clin. Microbiol. Infect,  15:S395.

  45. Elliott, BA, McGlasson, M, Painter P, Mann L, Hail D, Battee L, Wallace RJ Jr. Comparison of antimicrobials (AM) including besifloxacin (BES), ciprofloxacin (CIP), gatifloxacin (GAT), moxifloxacin (MOX), levofloxacin (LEV), azithromycin (AZ), clarithromycin (CL), amikacin (AK), Imipenem (IPM), and tobramycin (TOB) against ophthalmic (OP) isolates of nontuberculous mycobacteria (TNM).  109th General Meeting, American Society for Microbiology, Philadelphia, PA, Abstr. U-041, p. 583, 2009.

  46. Wnek M, Sholtis M, Tuohy MJ, Brown-Elliott B, Hall GS:  Can rapid Nocardia species identification empirically predict in-vitro susceptibility testing results?  108th General Meeting, American Society for Microbiology, Boston, MA, Abstr.C-025, p. 131, 2008.

  47. Balada-Llasat JM, Wallis C, Brown-Elliott BA, Wallace RJ, Fang FC:  Rapid detection of Mycobacterium spp. resistance to antimicrobial agents by real-time reverse transcription PCR.  108th General Meeting, American Society for Microbiology, Boston, MA, Abstr. C-211, p. 173, 2008.

  48. Hall L, Abbenyi AT, Eisberner JJ, Brown-Elliott BA, Pratt CJ, Beierle K, McGlasson M, Wohlfiel SL, Deml SM, Wallace RJ Jr., Wengenack NL:  Evaluation of clarithromycin drug susceptibility testing for Mycobacterium avium/intracellulare complex (MAC) using commercially available MAISLOW Sensititre® plates and custom JustOne strips.  108th General Meeting, American Society for Microbiology, Boston, MA, Abstr. C-202, p. 171, 2008.

  49. Thibert L, Brown-Elliott B, McNulty S, Wallace RJ Jr:  Strain comparison by randomly amplified polymorphic DNA PCR of multiple species of the Mycobacterium avium complex found within the same clinical samples in a public health laboratory in Quebec, Canada.  108th General Meeting, American Society for Microbiology, Boston, MA, Abstr.U-084, p. 678, 2008.

  50. Brown-Elliott BA, Beierle K, McGlasson M, Wallace RJ Jr.: Determination of MICs of Nocardia using the Trek Vizion™ System (VIZ) compared to manual readings.  108th General Meeting, American Society for Microbiology, Boston, MA, Abstr. U-084, p. 690, 2008.

  51. Brown-Elliott BA, Beierle K, McGlasson M, Wallace RJ Jr.:  MICs of nontuberculous mycobacteria using the TREK Vizion™ system compared to manual readings.  18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).  Barcelona, Spain, Abstr. on CD 2092, 2008.

  52. Brown-Elliott BA, Mann L, McGlasson M, Wilson R, Wallace RJ Jr.:  Comparison of in vitro activity of tigecycline (TIG) and minocycline (MIN) against isolates of the nocardiae.  107th General Meeting, American Society for Microbiology, Toronto, ON, Canada, Abstr. C-038, 2007.

  53. Zhang Y, Mann L, Brown-Elliott B, Janda WM, Schreckenberger PC, Warshauer D, Jost KC Jr, Wallace RJ Jr:  Population study of Mycobacterium lentiflavum isolates in the USA.  106th General Meeting, American Society for Microbiology, Orlando, FL, Abstr.U-009, 2006.

  54. Brown-Elliott BA, McGlasson M, Hildreth E, Kennedy K, Langsjoen B, Wallace RJ Jr:  Broth microdilution (BMD) drug combination studies against pulmonary isolates of Mycobacterium avium complex (MAC).  106th General Meeting, American Society for Microbiology, Orlando, FL, Abstr. 039, 2006.

  55. Brown-Elliott BA, Crist CJ, Spencer BG, Wallace RJ Jr:  Comparison of in vitro activity of imipenem (IPM), meropenem (MER), and ertapenem (ERT) against isolates of rapidly growing mycobacteria (RGM).  105th General Meeting, American Society for Microbiology, Atlanta, GA, Abstr. U-003, p. 56, 2005.

  56. Cloud JL, Hoggan K, Belousov E, Cohen S, Brown-Elliott BA, Mann L, Wilson R, Aldous W, Wallace RJ Jr, Woods GL:  Differentiation of Mycobacterium chelonae and M. abscessus using SmartCycler PCR and MGB Eclipse Probes.  105th General Meeting, American Society for Microbiology, Atlanta, GA, Abstr.C-024, p. 44, 2005.

  57. Holliday N, Knapp CC, Killian SB, Hall GS, Tuohy MJ, Wilson D, Body BA, Brown-Elliott BA, Warshauer D, Wengenack N, Deml S, Wolfe J, Woods GL, Cohen S:  Mycobacterium peregrinum ATCC 700686 susceptibility testing:  A multi site evaluation to establish microbroth dilution quality control (QC) ranges for 5 antimicrobial agents.  105th General Meeting, American Society for Microbiology, Atlanta, GA, Abstr. C-020, p. 43, 2005.

  58. Nash KA, Andini N, Zhang Y, Brown-Elliott BA, Wallace RJ Jr:  Adenine rRNA methylase or erm genes and macrolide resistance in rapidly growing mycobacteria.  44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC,  Abstr. C1-407, p. 67, 2004.

  59. Wilson RW, Conville PS, Mann L, Brown-Elliott BA, Crist C, Witebsky FG, Wallace RJ Jr:  Comparison of PCR restriction enzyme pattern analysis (PRA) of heat shock protein (hsp)65 and 16S rDNA gene fragments from isolates of Nocardia nova complex reveals species heterogeneity.  104th General Meeting, American Society for Microbiology, New Orleans, LA, Abstr. U-075, p. 636, 2004.

  60. Zhang Y, Brown-Elliott BA, Gravis EA, Williams-Bouyer N, Conger N, Yakrus MA, Butler WR, Wallace RJ Jr:  Molecular analysis of Mycobacterium simiae isolates from the United States.  104th General Meeting, American Society for Microbiology, New Orleans, LA,  Abstr. U-069, p. 635, 2004.

  61. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr.:  Identification of an rRNA methylase gene, erm(39), which confers inducible macrolide resistance to M. fortuitum.  104th General Meeting, American Society for Microbiology, New Orleans, LA, Abstr. U-017, p. 625, 2004.

  62. Tuohy MJ, Farrell JJ, Brown-Elliott B, Mann L, Wilson R, Wallace RJ Jr., Hall GS, Procop GW:  Evaluation of pyrosequencing™ for the identification of Nocardia species.  104th General Meeting, American Society for Microbiology, New Orleans, LA, Abstr. C-017, p. 124, 2004.

  63. Crist CJ, Brown-Elliott BA, Mann LB, Wallace RJ Jr:  Susceptibility of newer agents including gatifloxacin, moxifloxacin, meropenem, and tigecycline against the genus Nocardia.  103rd General Meeting, American Society for Microbiology, Washington, DC, Abstr. U-088, p. 648, 2003.

  64. Wallace RJ Jr, Brown-Elliott BA, Silcox V, Tsukamura M, Blacklock Z, Wilson RW, Mann LB, Zhang Y, Jost KC Jr, Brown JM, Schinsky MF, Steigerwalt A, Crist CJ, Hall L, Roberts GD:  Clinical and laboratory features of Mycobacterium porcinum.  103rd General Meeting, American Society for Microbiology, Washington, DC, Abstr.U-027, p. 637, 2003.

  65. Griffith DE, Brown-Elliott BA, Wallace RJ Jr:  Macrolide resistant Mycobacterium avium complex (MAC) lung disease.  2003 American Thoracic Society International Conference, Seattle, WA. American Journal of Respiratory and Critical Care Medicine, Abstr. A434, p. 167, 2003.

  66. Brown-Elliott BA, Wallace RJ Jr, Griffith DE, Lakey D, Moylett E, Gareca M, Perry TR, Blinkhorn R, Hopper D:  Safety and tolerance of long-term therapy of linezolid for mycobacterial and nocardial disease with a focus on once daily therapy.  40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL.  Abstr. 609, p. 151, 2002.

  67. Gareca MG, Brown-Elliott BA, Wallace RJ Jr:  Successful treatment of a clarithromycin-resistant Mycobacterium chelonae infection with linezolid.  40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL.  Abstr. 265, p. 91, 2002.

  68. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW: Comparison of the in vitro activity of levofloxacin and ciprofloxacin against the pathogenic rapidly growing mycobacteria.  42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, Abstr. E-541, 2002.

  69. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, Mann LB, Wilson RW: In vitro activity of linezolid against slowly growing nontuberculous mycobacteria.  42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, Abstr. E-535, 2002.

  70. Zhang Y, Lakey D, Wu S, Brown-Elliott BA, Wallace RJ Jr:  Detection of amikacin and clarithromycin ribosomal mutational resistance in Mycobacterium abscessus and Mycobacterium chelonae by the TaqManT probe allelic discrimination assay.  102nd General Meeting, American Society for Microbiology, Salt Lake City, UT, Abstr. U21, p. 479, 2002.

  71. Brown-Elliott BA, Wallace RJ Jr, Crist CJ: Comparison of in vitro activity of gatifloxacin (GATI) and ciprofloxacin (CIPRO) against three taxa of rapidly growing mycobacteria.  41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Abstr, E-723, p. 179, 2001.

  72. Wallace RJ Jr, Brown-Elliott BA, Crist CJ: Comparison of in vitro activity of GAR-936 with tetracycline, minocycline, and doxycycline in isolates of nontuberculous mycobacteria.  41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Abstr. E-525, p. 173, 2001.

  73. Urban A, Safdar N, Wand P, Brown-Elliott B, Wallace RJ. Jr.: A cluster of Mycobacterium lentiflavum clinical isolates originally identified as M. simiae complex.  39th Annual Meeting, Infectious Diseases Society of America (IDSA), San Francisco, CA.  Abstr. 333, p. 96, 2001.

  74. Schinsky MF, Douglas MP, Steigerwalt AG, Wilson RW, Floyd MM, Daneshvar MI, Brown-Elliott BA, Wallace RJ Jr, McNeil MM, Brenner DJ, Brown JM: Description of Mycobacterium bonickei sp. nov. (including two genomospecies), Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov., Mycobacterium concordense sp. nov., Mycobacterium brisbanense sp. nov., Mycobacterium fortuitum subsp. pseudoperegrinum subsp. nov., and Mycobacterium fortuitum subsp. fortuitum subsp. nov.  12th International Symposium on the Biology of Actinomycetes, The University of British Columbia, Vancouver, Canada, Abstr.117, p. 112, 2001.

  75. Brown-Elliott BA, Crist CJ, Ward SC, Wallace RJ Jr: Comparison of the in vitro susceptibility of cefepime with ceftriaxone and cefotaxime against clinical isolates of Nocardia.  101st General Meeting, American Society for Microbiology, Orlando, FL.  Abstr. C-374, p. 238, 2001.

  76. Crist CJ, Wallace RJ Jr, Brown-Elliott BA, Mann LB: Vancomycin susceptibility by broth microdilution MIC of species within the M. fortuitum group.  101st General Meeting, American Society for Microbiology, Orlando, FL.  Abstr. U-35, p. 705, 2001.

  77. Zhang Y, Mann LB, Wilson RW, Brown-Elliott BA, Vincent V, Wallace RJ Jr: Molecular analysis of Mycobacterium kansasii isolates from the United States.  101st General Meeting, American Society for Microbiology, Orlando, FL. Abstr.U-14, p. 700, 2001.

  78. Tiwari TSP, Ray B, Jost KC, Rathod MK, Zhang Y, Brown-Elliott BA, Hendricks K, Wallace RJ Jr: An outbreak of postinjection Mycobacterium abscessus infections caused by contamination of the disinfectant benzalkonium chloride.  101st General Meeting, American Society for Microbiology, Orlando, FL.  Abstract U-11, p. 700, 2001.

  79. Griffith DE, Brown-Elliott BA, McLarty J, Shepherd S, Griffith L, Wallace RJ Jr:  Ethambutol (EMB) ocular toxicity during therapy for Mycobacterium avium complex  (MAC) lung disease. American Thoracic Society International Conference, San Francisco, CA, American Journal of Respiratory and Critical Care Medicine, Abstr. A763, p. 163, 2001.

  80. Griffith DE, Brown-Elliott BA, Wallace RJ Jr:  An intermittent clarithromycin (CLARI)-containing regimen for Mycobacterium kansasii lung disease.  2001 American Thoracic Society International Conference, San Francisco, CA, American Journal of Respiratory and Critical Care Medicine, Abstr. A762, p. 163, 2001.

  81. Brown-Elliott BA, Ward SC, Crist CJ, Mann L, Wilson RW, Wallace RJ Jr: The activity of the oxazolidinone linezolid against the genus Nocardiae.  Nocardiae 2000: 2nd International Conference on the Biology of Nocardiae, University of California at Davis, Abstr. 163, 2000.

  82. Williams-Bouyer N, Wallace RJ Jr, Jost KC Jr, Brown BA, Woods GL: Clinical evaluation of DNA-DNA hybridization for identification of mycobacteria.  100th General Meeting, American Society for Microbiology, Los Angeles, CA.  Abstr.C-10, p. 128, 2000.

  83. Zhang Y, Brown BA, Böttger REC, Prammananan T, Sander P, Meier A, Frischkorn K, Wallace RJ Jr: Detection of amikacin resistance in Mycobacterium abscessus and Mycobacterium fortuitum by PCR restriction analysis (PRA).  100th General Meeting, American Society for Microbiology, Los Angeles, CA.  Abstr. U-6, p. 643, 2000.

  84. Brown BA, Ward SC, Mann L, Wilson RW, Wallace RJ Jr: In vitro activity of linezolid against multiple species of Nocardia: A new drug of choice for a difficult disease? 100th General Meeting, American Society for Microbiology, Los Angeles, CA.  Abstr. U-57, p. 654, 2000.

  85. Wallace RJ Jr, Brown BA, Ward SC, Mann L, Wilson R:  In vitro activity of linezolid against isolates of rapidly growing mycobacteria.  100th General Meeting of the American Society for Microbiology, Los Angeles, CA. Abstr. U-56, p. 654, 2000.

  86. Wallace RJ Jr, Zhang Y, Brown BA, Griffith DE, Couch L, Girard WE: Fingerprinting of late positive cultures in Mycobacterium avium complex lung disease treated with macrolide regimens using pulsed field gel electrophoresis. The Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones (ICMASKO), Seville, Spain, Abstr. 8.15, p. 73, 2000.

  87. Brown BA, Ward SC, Mann L, Wilson RW, Wallace RJ Jr: In vitro activity of linezolid against multiple species of Nocardia: A new drug of choice for a difficult disease?  The Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones (ICMASKO), Seville, Spain, Abstr. 8.15, p. 73, 2000.

  88. Fraser SL, Plemmons RM, Dooley DP, Davis CE, Garces MC, Brown BA, Grubber D, Wallace RJ:  Identification and control of an outbreak of rapidly growing mycobacterial infections in a bone marrow transplant unit.  37th Annual Meeting, Infectious Disease Society of America (IDSA), Philadelphia, PA, Abstr. 469, p. 121, 1999.

  89. Brown BA, Springer B, Steingrube VA, Wilson RW, Pfyffer GE, Garcia MJ, Menendez MC, Rodriguez-Salgado B, Jost KC Jr, Chiu SH, Onyi GO, Böttger EC, Wallace RJ Jr: Description of Mycobacterium wolinskyi and Mycobacterium goodii, two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections.  99th General Meeting, American Society for Microbiology, Chicago, IL, Abstr. U-47, p. 80, 1999.

  90. Jost KC Jr, Chiu SH, Dunlap RB, Elliott LB, Brown BA, Steingrube VA, Wilson RW, Wallace RJ Jr: High-performance liquid chromatographic characterization of Mycobacterium smegmatis and closely related species.  99th General Meeting, American Society for Microbiology, Chicago, IL, Abstr. U-36, p. 80, 1999.

  91. Zhang Y, Brown BA, Böttger EC, Prammananan T, Sander P, Meier A, Frischkorn K, Wallace RJ Jr: Detection of clarithromycin and amikacin mutational resistance in Mycobacterium chelonae-abscessus by use of a RNA/RNA mismatch assay.  99th General Meeting, American Society for Microbiology, Chicago, IL, Abstr. U-5, p. 46, 1999.

  92. Griffith DE, Brown BA, Shepherd S, Murphy D, Griffith B, Wallace RJ Jr: Current epidemiology of Mycobacterium avium complex lung disease in HIV negative patients.  1999 American Thoracic Society International Conference, San Diego, CA, American Journal of Respiratory and Critical Care Medicine, Abstr. 159:A903, 1999.

  93. Brown BA, Onyi GO, Wallace RJ Jr: Susceptibility Testing of Rapidly Growing Mycobacteria (RGM), to a New Everninomicin, SCH27899.  The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California,  Abstr. E-128, p. 206, 1998.

  94. Wilson RW, Steingrube VA, Böttger EC, Springer B, Brown BA, Jost KC Jr., Zhang Y, Onyi G, Nash DR, Wallace RJ Jr: Recognition of a New Taxon Within the Mycobacterium abscessus-Mycobacterium chelonae Complex and Proposal of Mycobacterium immunogen sp. nov.  98th General Meeting, American Society for Microbiology, Atlanta, Georgia, Abstr. C6, 1998.

  95. Brown BA, Thibert L, Wanger A: Use of E-test for Clarithromycin Susceptibility Testing of Mycobacterium haemophilum. 98th General Meeting, American Society for Microbiology, Atlanta, Georgia, Abstr. U4, 1998.

  96. Wallace RJ Jr., Zhang Y, Brown BA, Dawson D, Murphy DT, Wilson R, Griffith DE:  Individual Patients with Nodular Bronchiectasis Lung Disease are Infected with Multiple Genotypes and Serovars of Mycobacterium avium Complex.  98th General Meeting, American Society for Microbiology, Atlanta, Georgia, Abstr. U2, 1998.

  97. Griffith DE, Brown BA, Wallace RJ Jr: Initial (six months) results of intermittent clarithromycin-containing regimens for Mycobacterium avium complex lung disease.  1998 American Thoracic Society International Conference, Chicago, IL, American Journal of Respiratory and Critical Care Medicine, Abstr. 157:A579, 1998.

  98. Griffith DE, Brown BA, Girard WM, Griffith BE, Wallace RJ Jr: Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.  1998 American Thoracic Society International Conference, Chicago, IL, American Journal of Respiratory and Critical Care Medicine, Abstr. 157:A579, 1998.

  99. Schinsky MF, Brown BA, Steingrube VA, Wallace RJ Jr., Brown JM: Genetic and Phenotypic Characterization of an Emerging Mycobacterium Species: Mycobacterium fortuitum Third Biovariant Complex (Mf) (Sorbitol-Negative).  International Conference on Emerging Infectious Diseases, Atlanta, Georgia, 1998.

  100. Brown BA, Wallace RJ Jr., Griffith DE, Onyi GO, Murphy DT: Clarithromycin Resistance in Patients on Multidrug Regimens for Mycobacterium avium Complex (MAC) Lung Disease. The Fourth International Conference on the Macrolides, Azalides, Streptogramins & Ketolides.  Barcelona, Spain, Abstr. 5.14, p. 56,  1998.

  101. Griffith DE, Wallace RJ Jr., Brown BA, Girard WM, Murphy DT, Griffith BE: Intermittent Versus Daily Azithromycin (AZI)-Containing Regimens for Treatment of Mycobacterium avium Complex (MAC) Lung Disease.  The Fourth International Conference on the Macrolides, Azalides, Streptogramins & Ketolides.  Barcelona, Spain, Abstr. 5.12, p. 55, 1998.

  102. Wallace RJ Jr., Griffith DE, Brown BA, Murphy DT: Initial (Six-Months) Results of Intermittent Clarithromycin (CLAR)-Containing Regimens for Mycobacterium avium Complex (MAC Lung Disease).  The Fourth International Conference on the Macrolides, Azalides, Streptogramins & Ketolides.  Barcelona, Spain, Abstr. 5.11, p. 55, 1998.

  103. Ho JE, Wong MT, Lattuada C Jr., DeGuide JJ, Dolan MJ, Brown BA, Melcher GP, Wallace RJ Jr: Mycobacterium fortuitum Infections After Automatic Cardiac Defibrillator and Pacemaker Implantation.  Society of Air Force Physicians, 1997.

  104. Wallace RJ Jr., Brown B, Springer B, Steingrube V, Wilson R, Pfyffer G, Jost K, Onyi G, Böttger E: Description of 3 New Taxa Related to Mycobacterium smegmatis Associated with Human Wound Infections.  18th Congress of the European Society of Mycobacteriology (ESM-97), Córdoba, Spain, p. 59, 1997.

  105. Zhang Y, Rajagopalan M, Brown BA, Wallace RJ Jr:  Random Amplified Polymorphic DNA (RAPD)-PCR for Strain Comparison of Mycobacterium avium-M. intracellulare Complex (MAC).  97th General Meeting, American Society for Microbiology, Miami Beach, Florida, Abstr. U-168, p. 572, 1997.

  106. Stone B, Burman W, Wilson M, Brown B, Wallace RJ Jr:  Evaluation of E-test to Determine Susceptibility of Mycobacterium avium Complex (MAC) to Clarithromycin (CLARI).  97th General Meeting, American Society for Microbiology, Miami Beach, Florida, Abstr. U-78, p. 557, 1997.

  107. Sander P, Prammananam T, Frischkorn K, Brown BA, Zhang Y, Wallace RJ Jr, Böttger EC: Genetic Basis for Resistance to Amikacin and the 2-Deoxystreptamine Aminoglycosides in Mycobacterium chelonae and M. abscessus (Mabs).  97th General Meeting, American Society for Microbiology, Miami Beach, Florida, Abstr. U-13, p. 546, 1997.

  108. Wilson RW, Steingrube VA, Brown BA, Wallace RJ Jr:   Clinical Application of PCR-RFLP Analysis for the Rapid Identification of Aerobic Actinomycetes.  97th General Meeting, American Society for Microbiology, Miami Beach, Florida, Abstr.C-66, p. 131, 1997.

  109. Brown BA, Wilson RW, Steingrube VA, Blacklock Z, Wallace RJ Jr:  Characterization of a Nocardia brevicatena Complex Among Clinical and Reference Isolates of Nocardia.  97th General Meeting, American Society for Microbiology, Miami Beach, Florida, Abstr. C-65, p. 131, 1997.

  110. Griffith DE, Brown BA, Murphy D, Girard WM, Wallace RJ Jr: Initial Results of Three Times Weekly Azithromycin (AZI) Containing Regimens for Mycobacterium avium Complex (MAC) Lung Disease.  1997 American Lung Association / American Thoracic Society International Conference, San Francisco, CA, Abstr. B-36, p. A334, 1997.

  111. Wilson RW, Brown BA, Steingrube VA, Blacklock Z:  Recognition of a Nocardia transvalensis Complex by DNA Amplification and Restriction Endonuclease Analysis.  96th General Meeting, American Society for Microbiology, New Orleans, Louisiana, Abstr. C-400??, p. 72, 1996.

  112. Brown BA, Wallace RJ Jr., Onyi O:  Activities of the Glycylcyclines N-N-Dimethylglycylamido Minocycline and N,N-dimethylglycylamido 6-demethyl-6-deoxytetracycline Against Nocardia sp. and Tetracycline Resistant Isolates of Rapidly Growing Mycobacteria.  96th General Meeting, American Society for Microbiology, New Orleans, Louisiana, Abstr. U-69, p. 113, 1996.

  113. Wallace RJ Jr., Brown BA, Meier A, Zhang Y, Böttger EC:  Genetic Basis for Clarithromycin Resistance Among Mycobacterium chelonae and Mycobacterium abscessus.  96th General Meeting, American Society for Microbiology, New Orleans, Louisiana, Abstr. U-84, p. 115, 1996.

  114. Lai KK, Fontecchio SA, Westerling JA, Melvin ZS, Brown BA, Zhang Y, Wallace RJ Jr: Pseudo-outbreak of Respiratory Infections due to Mycobacterium abscessus.  6th Annual Meeting of The Society for Healthcare Epidemiology of America, Washington, DC, 1996.

  115. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Murphy D: Clarithromycin (CLARI) Regimens for Pulmonary Mycobacterium avium-intracellulare (MAI) in Non-AIDS: Long Term Follow-up of the First 50 Patients.  The Third International Conference on the Macrolides, Azalides, and Streptogramins.  Lisbon, Portugal, 1996.

  116. Wallace RJ Jr, Griffith DE, Brown BA, Murphy D, Girard W, Cegielski JP: Initial Results of Three Times Weekly Azithromycin (AZI) in Treatment Regimens for Mycobacterium avium-intracellulare (MAI) Lung Disease in Non-AIDS. The Third International Conference on the Macrolides, Azalides, and Streptogramins.  Lisbon, Portugal, 1996.

  117. Pang Y, Brown BA, Steingrube VA, Wallace RJ Jr., Roberts MC: Tetracycline Resistance Determinants in Clinical Isolates of Mycobacterium intracellulare/avium and Nocardia spp.  35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1995.

  118. Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT: Clarithromycin Containing Regimens for the Treatment of Mycobacterium avium-intracellulare Lung Disease: the First 50 Patients.  30th Joint Leprosy/Tuberculosis Conference, Fort Collins, Colorado, 1995.

  119. Meier A, Wallace RJ Jr., Brown BA, Sander P, Heifets L, Böttger EC: Molecular Mechanisms of Resistance to Clarithromycin in Mycobacterium avium-intracellulare Complex.  95th General Meeting, American Society for Microbiology, Washington, DC, Abstr. U-41, p. 124, 1995.

  120. Griffith De, Brown BA, Girard WM, Wallace RJ Jr: Adverse Events Associated with High Dose Rifabutin (RBT) in Macrolide-Containing Regimens for Mycobacterium avium-intracellulare (MAI) Lung Disease.  American Thoracic Society International Conference.  Seattle, Washington, 1995.

  121. Griffith DE, Wallace RJ Jr, Brown BA, Girard WM, Murphy DT, Onyi GO: Azithromycin (AZITH) Monotherapy (Mono-Rx) for HIV (-) Patients with Mycobacterium avium intracellulare Complex (MAI) Lung Disease.  American Thoracic Society International Conference.  Seattle, Washington, 1995.

  122. Wallace RJ Jr., Brown BA, Griffith DE, Girard W, Tanaka K: Reduced Serum Levels of Clarithromycin in Patients on Multidrug Regimens Including Rifampin or Rifabutin for Treatment of Mycobacterium avium-intracellulare (MAI).  34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, Abstr. M-59, p. 246, 1994.

  123. Pang Y, Brown BA, Steingrube VA, Wallace RJ Jr., Roberts MC:  Tetracycline Resistance Determinants in Clinical Isolates of Mycobacterium fortuitum and M. avium Isolates.  94th General Meeting, American Society for Microbiology,  Las Vegas, Nevada, Abstr. U-131, p. 154, 1994.

  124. Steingrube VA, Brown BA, Rajagopalan M, Wilson B, Wallace RJ Jr:  Polymerase Chain Reaction (PCR) Amplification and KDal Heat Shock Protein Gene for Taxonomic Separation of the Rapidly Growing Mycobacteria (RGM).  94th General Meeting, American Society for Microbiology, Las Vegas, Nevada, Abstr. U-37, p. 32, 1994.

  125. Brown BA, Steingrube VA, Wallace RJ Jr:  Pulsed-field Gel Electrophoresis (PFGE) for Evaluation of Repeat Isolates of Mycobacterium avium Complex (MAC) Including Isolates Resistant to Clarithromycin (CLARI).  94th General Meeting, American Society for Microbiology, Las Vegas, Nevada, Abstr. U-35, p. 32, 1994.

  126. Griffith DE, Wallace RJ Jr., Brown BA, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH: Clarithromycin (CLAR) Monotherapy for Mycobacterium avium intracellulare Complex (MAI) Lung Disease.  American Thoracic Society International Conference, Boston, Massachusetts, 1994.

  127. Pang Y, Wallace RJ Jr, Brown BA, Steingrube VA, Roberts MC:  Mechanism of Tetracycline Resistance in M. fortuitum group and Streptomyces species.  Molecular Mechanisms of Drug Resistance, Albany Conference, 1993.

  128. Griffith DE, Brown BA, Blinkhorn RJ, Wallace RJ Jr: Treatment of Mycobacterium abscessus Lung Disease with Clarithromycin.  American Thoracic Society International Conference, San Francisco, California, 1993.

  129. Brown BA, Wallace RJ Jr, Mullins RD, Onyi GO: Activities of Four Macrolides and Tobramycin Against Human Isolates of Rhodococcus equi. 93rd General Meeting, American Society for Microbiology, Atlanta, Georgia, Abstr. A-26, p. 5, 1993.

  130. Wallace RJ Jr, Zhang Y-S, Fraser V, Brown BA:  DNA Large Restriction Fragment Pattern Analysis of Sporadic and Epidemic Nosocomial Strains of Mycobacterium chelonae and Mycobacterium abscessus.  93rd General Meeting, American Society for Microbiology, Atlanta, Georgia, Abstr. L-18, p. 547, 1993.

  131. Griffith DE, Brown BA, Blinkhorn RJ, Wallace RJ Jr:  Treatment of Mycobacterium abscessus Lung Disease with Clarithromycin.  International Conference of the American Thoracic Society (ATS), San Francisco, California, 1993.

  132. Wallace RJ Jr, Brown BA, Griffith D.:  Drug Intolerance to Clarithromycin Among Elderly Patients Treated for Mycobacterium avium-complex Lung Disease.  Frontiers in Mycobacteriology: M. avium, the Modern Epidemic, Vail, Colorado, 1992.

  133. Wallace RJ Jr, Brown BA, Griffith D, Girard W, Murphy D, Onyi G.:  Preliminary Results of Low Dose Clarithromycin Monotherapy for Mycobacterium avium-intracellulare Complex (MAI) Lung Disease.  Frontiers in Mycobacteriology: M. avium, the Modern Epidemic, Vail, Colorado, 1992.

  134. Wallace RJ Jr, Brown BA, Tanner D, Brennan PJ, Blahunka KS, Craft JC:  An Open Trial of Clarithromycin (CLAR) in Therapy of (Disseminated) Cutaneous Infection Due to Mycobacterium chelonae subsp chelonae (Mcc).  32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Anaheim, California, 1992.

  135. Brown BA, Onyi GO: Activity of clarithromycin against slow-growing nontuberculous mycobacteria using a broth microdilution MIC system. 92nd General Meeting, American Society for Microbiology, New Orleans, Louisiana, Abstr. U-84, p. 203, 1992.

  136. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA, Craft JC, Blahunka K: Preliminary results of an open noncomparative trial of clarithromycin in the therapy of (disseminated) infection due to Mycobacterium chelonae subsp. chelonae (MCC).  First International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992.

  137. Wallace RJ Jr, Brown BA, Onyi GO: Activity of Clarithromycin Against Slow-Growing Nontuberculous Mycobacteria Using a Broth Microdilution MIC System.  First International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992.

  138. Wallace RJ Jr, Brown BA, Onyi GO, DeRosas V, Wallace RJ III:  Activities of Four Macrolides Including Clarithromycin (CLAR) Against Mycobacterium fortuitum and Mycobacterium chelonae.  First International Conference on the Macrolides, Azalides, and Streptogramins, Santa Fe, New Mexico, 1992.

  139. Wallace RJ Jr, Brown BA, Stocks JM, Griffith DE, Mazurek GH: Comparative Trial of Cefixime (FIX) and Amoxicillin/Clavulanic Acid (A/C) in Adult Lower Respiratory Infections Due to Moraxella catarrhalis (M. cat) and Haemophilus influenzae (H. flu).  17th International Congress of Chemotherapy, Berlin, Germany, 1991.

  140. Steingrube VA, Brown BA, Zhang Y: Correlation of b-lactamase Isoelectric Focusing (IEF) Patterns with b-lactam Resistance Patterns in Nocardia asteroides Complex.  91st General Meeting, American Society for Microbiology, Dallas, Texas, Abstr. A-33, p. 6, 1991.

  141. Brown BA, Wallace RJ III, DeRosas MV, Onyi GO, Wallace RJ Jr: The Activity of the Newer Macrolides Including Clarithromycin Compared to Erythromycin Against Mycobacterium chelonae.  91st General Meeting, American Society for Microbiology, Dallas, Texas, Abstr. U-62, p. 152, 1991.

  142. Pang Y, Hector JSR, Mazurek G, Zhang Y, Brown BA, Wallace RJ Jr:  Use of Pulsed Field Gel Electrophoresis (PFGE) of Large Genomic DNA Restriction Fragments for Studying Nosocomial Diseases Due to Mycobacterium fortuitum.  91st General Meeting, American Society for Microbiology, Dallas, Texas, Abstr. U-63, p. 153, 1991.

  143. Wallace RJ Jr, Brown BA, Onyi GO: Activity of Newer Beta Lactams Against Three Subgroups of Rapidly Growing Mycobacteria.  30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, 1990.

  144. Wallace RJ Jr, Nash DR, Silcox VA, Tsukamura M, Brown BA, Steele LC, Steingrube VA, Blacklock Z, Smith JM, Sumter G, Zhang Y: Clinical Disease, Drug Susceptibility, and Biochemical Patterns of the Unnamed Third Biovariant Complex of Mycobacterium fortuitum.  90th General Meeting, American Society for Microbiology, Anaheim, California, Abstr. U-70, p. 153, 1990.

  145. Wallace RJ Jr, Steingrube VA, Hollis D, Flanagan C, Brown BA, Labidi A, Nash DR, Weaver R: The BRO b-lactamases of Branhamella catarrhalis and Subgenus Moraxella, with Evidence for Chromosomal Conjugal b-lactamase Transfer in B. catarrhalis, M. nonliquefaciens, and M. lacunata. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, Abstr. U-757, p. 228, 1989.

  146. Wallace RJ Jr: Incidence and mechanisms of antibiotic resistance, among lower respiratory tract pathogens. In: Symposium Proceedings on New Approaches to Antimicrobial Therapy, Alto Ochsner Institute, pages 23-27, 1987.